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Abstract
Background: Fibromyalgia (FM) is characterized by chronic diffuse pain, fatigue,
memory problems, sleep disturbance, depression, and mobility limitations. The
Department of Defense (DoD) and Department of Veterans Health Administration (VA)
recognize FM as potentially connected to service in the Persian Gulf War, and the rates of
FM diagnosis and disability in the VA are rising.
Purpose: The purpose of this dissertation was to assess the feasibility and acceptability
of heart rate variability biofeedback (HRVB) as an intervention for the treatment of FM
in Veterans.
Problem/Aims: We conducted an integrative literature review (manuscript 1) and
identified a gap in the literature related to HRVB to treat FM-related chronic pain.
Overall, HRVB is a promising treatment for chronic pain; however, further research is
needed to evaluate the relationship between HRVB and FM pain. We found only one
study evaluating HRVB for the treatment of FM, and we did not identify any studies that
evaluated the recommended HRVB practice protocols, or any qualitative studies
investigating the individual experience of using HRVB. The specific aims of this
dissertation were:
Aim 1: Examine the feasibility of recruitment and retention of Veterans with
fibromyalgia.
Aim 2: Determine the feasibility of adherence to the recommended HRVB
practice protocol using the emWave2.
Aim 3: Examine participant acceptability and satisfaction with the intervention.
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Design: We used a sequential exploratory multi-method design to determine if it is
feasible for Veterans with FM to follow a twice-daily 20-minute HRVB practice
protocol. We conducted a focus group post-intervention to explore the participant’s
experiences with HRVB.
Theoretical framework: The theory of symptom self-management guided the study; it
posits that when self-directed interventions are optimized, performance outcomes will
improve.
Findings: We found that it was not feasible for Veterans with FM to follow the
recommended HRVB protocol. Barriers identified were conflicts with family obligations
and work schedule as well as difficulties operating the HRVB device. Results from
weekly questionnaires suggested an improvement in functional status and quality of life,
but no change in pain levels. However, during the focus group discussion, the Veterans
reported a reduction in pain levels as well as improvement in sleep, relaxation, and
cognition.
Conclusion: Limitations of this study were a small size (n=10), possible self-selection
bias, and the lack of a control group. While the data suggests HRVB may improve the
functional status and quality of life of those with FM, more research is needed.
Keywords: fibromyalgia, chronic pain, heart rate variability biofeedback, veterans,
integrative literature review, feasibility, acceptability, practice protocol.
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Introduction
Fibromyalgia (FM), a complex chronic pain syndrome, affects 10 million
individuals in the United States (1, 2). The associated fatigue, memory problems, sleep
disturbance, depression, anxiety, cognitive impairment, and mobility limitations (2, 3)
contribute to 1-2% loss of national productivity (4, 5), $12-14 billion per year in national
health care costs (4), and individual deficits in quality of life (6).
FM is recognized by the Department of Defense (DoD) and Department of
Veterans Health Administration (VA) as potentially connected to service in the Persian
Gulf War (7). The DoD and VA have linked FM to the physical and emotional trauma
sustained by service members who deployed during the war as well as to the various
natural and man-made environmental exposures in that region (8). Repetitive muscular
injuries are attributed to service members carrying over 80 pounds of equipment daily for
6-12 months, during multiple deployments between October 2001 and the present; this
has resulted in more than 50% of service members/Veterans returning from these
conflicts reporting chronic pain not related to direct injuries such as shrapnel, gun shots,
or blasts (8-10). The rate of diagnosis and disability of Veterans is rising at an alarming
rate (11). With ongoing conflicts around the world, we do not expect the rate of FM cases
to decrease. As health care providers in the VA it is our mission to fulfill President
Lincoln’s promise “to care for him who shall have borne the battle”(12), and to honor the
VA core value of excellence by striving for the highest quality and continuous
improvement in care. Thus, we chose to focus our study on the Veteran population,
whom we recruited as study participants.
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Because of the complexity of symptoms reported by individuals with FM, and the
unclear etiology of the disease, primary care physicians and advanced practice nurses
have had difficulty diagnosing and treating these patients. The diagnostic criteria for FM
have changed significantly in recent years. The initial diagnostic criteria set by the
American College of Rheumatology (ACR) in 1990 was determined by the number of
“tender points” reported by the patient during a time-consuming, complex physical exam
(13). In 2010 the ACR determined that 25% of patients with FM did not meet the
“tender-point” test of FM and modified the survey to address the associated fatigue,
sleep, and cognitive changes (2). “Tender-points” are subjective reports of pain or
discomfort when the practitioner applies pressure specified areas of the head, neck, chest,
back, and extremities (2). FM diagnosis was satisfied with one of the following 3
conditions: 1) the Widespread Pain Index (WPI) ≥ 7, the Symptom Severity Score (SS) ≥
5, or the WPI = 36 and the SS ≥ 9; 2) symptoms present and at a similar level for at least
3 months, or 3) the patient lacked a disorder that would otherwise explain the pain (2).
The initial survey was self-administered by the patient and then completed by the
physician after a physical exam. Wolfe et al. (14) developed a modification of the 2010
criteria that allows complete self-administration by the patient. Primary care physicians
and advanced practice nurses can give the survey to patients and easily interpret the
results without a visit to a specialist, such as a rheumatologist. The developers argue this
practice could decrease time to diagnosis and treatment (14). Additionally, the modified
survey identifies a higher FM prevalence and a larger proportion of men with FM (15).
The diagnostic sensitivity to men in the modified survey may explain the increased rate
of FM diagnosis among service members and Veterans.
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Individuals with FM often report symptoms that are variable and unpredictable,
leading to frustrations around reporting their symptoms and often feeling as if the health
care provider does not believe them (16, 17). Individuals with FM are also frustrated by
the lack of clarity of a diagnosis, which leads to skepticism from family, friends, and
health care professionals(16). Additionally, patients reported they are often given very
little if any information about FM by their health care provider, and have to seek answers
from other patients, support groups, or family members with the same diagnosis (17). FM
patients are often skeptical of treatment recommendations, especially medications,
because prescribing physicians have difficulty explaining how the treatment will target
their symptoms or disease (17). FM patients report they are often better understood and
receive more acceptable treatment from holistic providers; however, these treatments are
often not covered by health insurance plans (16).
Treatment Recommendations
Health care providers agree that symptoms associated with FM are generally not
demonstrated in chronic headaches, back, joint, or neck pain; thus, comparing treatment
among these pain syndromes is challenging (2, 6). The VA/DoD has published clinical
guidelines for chronic pain management (18). The most common published guidelines for
FM treatment are from the European League Against Rheumatism (EULAR) 2016; the
American Pain Society (APS) 2005; the German Association of the Scientific Medical
Societies (AWMF) 2013; the Israeli Pain Society (IPS); and the Canadian Pain Society
(CPS) (15, 19). Recent research and findings of the etiology and pathophysiology of FM
indicate treatment must be multi-focal (15). There is a consensus among the EULAR,
APS, AWMF, IPS, and CPS guidelines that effective treatment must include a
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multidisciplinary approach that prioritizes nonpharmacological treatments, offers
judicious pharmacological treatments (15, 19), and are based on the biopsychosocial
model (15).
Pharmacological therapies. Pharmacological treatment guidelines vary greatly,
which increases the difficulty in treating FM. VA/DoD treatment guidelines recommend
against the use of opioids to treat FM-related chronic pain (18). EULAR and AWMF do
not recommend common non-opioid analgesic treatments such as non-steroidal antiinflammatories (NSAID) (20). There is no evidence for the effective use of
acetaminophen or topical creams/ointments (1, 15, 21). Importantly, AWMF and EULAR
strongly recommend against the use of opioids (15, 21). The published World Health
Organization pain ladder includes opioids. However, it was designed for chronic pain
related to cancer and is not appropriate for the treatment of widespread chronic pain as is
seen in FM (15). The antidepressant amitriptyline has some evidence for both the
treatment of neuropathic pain and sleep disturbance and received varying
recommendations from all four guidelines (15). CPS guidelines recommend gabapentin
and pregabalin, although EULAR gives them a weak recommendation, and AWMF
recommends the use of pregabalin only if the use of amitriptyline is not possible, and
does not make any decision about gabapentin (21). AWMF, CPS, and EULAR
recommend serotonin-norepinephrine uptake inhibitors (SNRI) like duloxetine, which
may provide some benefit (21). Milnacipran, a newer SNRI, is only recommended in the
EULAR guidelines and not recommended in the AWMF guidelines (21).
Nonpharmacological therapies. All treatment guidelines agree that FM
management should include a personalized graded exercise program (15, 19). A meta-
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analysis of randomized controlled trials examining the effects of exercise on FM
symptoms of fatigue, physical functioning, depression, and quality of life support this
recommendation (22). All guidelines except EULAR include psychological treatment that
includes cognitive behavior therapy a “strong recommendation” (15, 19, 20).
Complementary and alternative medicines (CAM) like acupuncture, Tai Qi, and
chiropractic treatments are controversial but encouraged in the CPS guidelines (15).
Currently, however, there is insufficient evidence to support the use of CAM (15). The
most recent VA/DoD Clinical Practice Guidelines for the treatment of chronic pain,
which includes pain related to fibromyalgia, is to utilize cognitive behavior therapy,
biofeedback, exercise, multidisciplinary psychosocial rehabilitation (3, 18), physical
therapy, occupational therapy, acupuncture, manipulation, and CAM (9, 15).
EULAR treatment guidelines only evaluated two reviews that included biofeedback as a
treatment for FM (20). EULAR committee members do not recommend biofeedback,
because while it is effective in reducing pain intensity it is not effective for fatigue or
sleep (20). The report did not specify the type of biofeedback evaluated.
Pathophysiology of FM
The symptoms of FM - fatigue, memory problems, sleep disturbance, depression,
anxiety, and cognitive impairment - are complex, and the above-referenced treatment
recommendations do not address recent findings of the etiology of FM (23, 24). Research
utilizing functional magnetic resonance imaging (fMRI) demonstrates that in individuals
with FM, there is a disruption of pain network connectivity. Strengthened connectivity of
the brain regions involved in the processing and reduced connectivity of the regions
involved in pain inhibitory modulation may explain this widespread chronic pain (23).
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The default mode network (DMN), a constellation of brain regions engaged in
self-referential thinking, is disrupted in FM during tasks like visual attention and
cognitive attention, which may explain symptoms of memory problems and cognitive
impairment (24). An abnormally increased level of connectivity between the DMN and
the insular cortex may also explain higher reported pain levels (25). Additionally, a
dysfunction of the cardiac autonomic nervous system (ANS), characterized by higher
sympathetic and lower parasympathetic cardiac autonomic modulation, is associated with
incoherent heart rate variability and is related to the impact of FM on quality of life (6,
26).
Heart Rate Variability
Heart rate variability (HRV) is the time measurement of the oscillations of the Rto-R intervals (27-29) (see Figure 1). HRV reflects heart-brain interaction and ANS
function (28-31) and HRV information on how the ANS interacts and functions as a
whole (32). Analyzing HRV provides quantitative information about the state of the ANS
(6).

Figure 1. Heart rate variability
Optimal HRV is cardiac coherence, a sine-waveform that is ordered and harmonic
(33). Coherent HRV reflects a healthy functioning system, adequate physical functioning,
minimal pain (28), resistance to stress, emotional adaptability (27), and self-regulation
(33) (see Figure 2). Conversely, an HRV measurement that is too little or chaotic is
incoherent (see Figure 2). An incoherent HRV reflects an ANS that is dysfunctional,
6

contributing to chronic pain, decreased physical functioning, and poor quality of life (6,
28, 31).

Figure 2. Heart rate variability waveform
Image retrieved from heartitelligence.com
With current technology, we can obtain HRV measurements non-invasively from
an electrocardiogram, pulse wave recordings, or a plethysmographic optical sensor placed
at the fingertip or on the earlobe (32). Devices that measure HRV using the fingertip or
earlobe sensor are easily used by professionals and non-specialists, are relatively
inexpensive, and can be used in the clinical setting as an educational tool for patients or
by patients at home to regulate emotional states, stress resistance, and quality of life (32).
Heart Rate Variability Biofeedback
Heart rate variability biofeedback (HRVB) (34) is an innovative, nonpharmacological self-management strategy that uses technology to induce a vagal
response as the individual slows their breathing rate to 4-6 breaths per minute (33). This
technologically-guided breathing produces a maximized respiratory sinus arrhythmia, a
coherent HRV (34). HRVB has the potential to improve emotion regulation, stress
resistance (35-37), and quality of life (33, 37, 38). Repeated sessions of HRVB can
sustain improved HRV coherence for longer periods and, with sufficient practice, can be
used by individuals before, during, and after times of increased stress, thus optimizing
7

stress resistance and emotional adaptability to decrease pain and increase overall wellbeing (33, 35, 37).
Lehrer et al. (39) determined individuals cannot simply achieve and sustain an
optimal breathing rate to reach HRV coherence without training with the developed
HRVB protocols. HRVB training must occur gradually to adjust to the decreased rate of
breathing of 4 to 6 breaths per minute (40). The emWave2 is a handheld visual HRVB
device. It is easy to use and available on the general market. A photoplethysmograph
(PPG) sensor is clipped on the participant’s ear and connected to the device. A blinking
blue light on the device indicates the device is reading the individual’s pulse (41). The
strip of light fluctuates between red, blue, and green as the individual breathes
rhythmically (see Figure 3). The individual is instructed to take slow, rhythmic breaths.
The goal is to increase HRC and change the coherence level indicator from red (low
coherence/baseline) to blue (medium coherence/improving) to green (high
coherence/optimal), and to remain in the green zone as long as possible during the
practice session (41). A trained registered nurse (RN) can teach a patient HRVB during a
routine primary care visit, thus allowing nurse practitioners and physicians time for
patient care needs that cannot be met by an RN independently (39).
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Figure 3. emWave2 Heart rate variability biofeedback device.
@www.heartmath.com/emwave2
Preliminary Work
We conducted an integrative literature review to examine the relationship between
HRVB and FM-related pain. We found six studies that examined the relationship
between HRVB and chronic pain; only one of the studies examined FM-related pain.
HRVB is a promising, effective treatment modality for chronic back pain, joint pain, neck
pain, and headaches. As stated earlier, FM-related pain is complex and includes
symptoms not usually seen in chronic headaches or musculoskeletal pain, and thus,
treatment cannot be the same. We identified that although incoherent HRV is associated
with FM-related symptoms, such as pain, mood disturbance, and fatigue, and coherent
HRV is associated with normal physical function, stress resistance, and emotional
stability, there is a lack of research investigating HRVB to treat FM-related chronic pain.
Theoretical Foundation
The primary complaints from those suffering from FM are symptoms of diffuse
pain, fatigue, changes in mood, sleep deprivation, and brain fog (15). The Theory of
Symptom Self-Management (TSSM) has been used to assist individuals in reducing,
preventing, relieving, or decreasing the frequency of unpleasant symptoms like those
experienced in FM, through self-management-enhancing interventions (SMI) (42, 43)
like HRVB (33, 38, 44). The central tenet of TSSM that guided this study is that by
optimizing self-directed SMI, such as HRVB, performance outcomes will improve.
The key concepts of TSSM are: 1) perceived self-efficacy for symptom self-management
(PSM), 2) symptom self-management, 3) patient characteristics, 4) symptoms, 5)
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performance outcomes, and 6) perceived self-efficacy-enhancing interventions (PSI) (43).
Figure 4 has been modified to illustrate the application of TSSM to HRVB.

Figure 4. Theory of Symptom Self-Management model to HRVB (43)
PSM is the confidence or belief of one’s own ability to implement or execute specific
behaviors to attain established goals or desired outcomes (43). We asked participants if
they believed HRVB would be an effective treatment before starting the study. We also
asked if they believed they were successful with the prescribed protocol and if they
believed they were able to affect change in their symptoms.
PSI includes self-management skills that support self-efficacy and improve selfcare (43). Participants in this study implemented HRVB to self-manage their FM-related
chronic pain. The participants evaluated the skill level of their self-management by
reading the output (light display) on the emWave2 device and adjusted their breathing
rate until they reached their goal of “green light.”
Symptom self-management encompasses self-directed active behaviors that may
identify, prevent, and relieve or decrease the timing, intensity, and distress of symptoms
like pain, fatigue, depression, and HRV (43). In this study, we followed the
10

recommendations by Lehrer et al. (39) and encouraged the participants to practice HRVB
for 20 minutes, twice daily. The participants had immediate feedback regarding optimal
use from the red, blue, and green display lights. Additionally, we reviewed the prior week
practice schedule with the participant and helped them identify any barriers to the
recommended practice schedules.
Performance outcomes are the effects of the individual’s symptom selfmanagement experience (43). The goal of HRVB is to decrease symptoms of pain,
depression, fatigue, and improve cognitive and physical function. These symptoms have a
direct effect on the performance outcomes of quality of life and functional status.
Methodology
We used a sequential exploratory multi-method design to assess the feasibility
and acceptability of HRVB as a treatment for FM. We conducted eight individual weekly
HRVB training sessions. We guided the participants’ practice of HRVB breathing
techniques for 20 minutes during each weekly session.
During each weekly session, we also collected and evaluated quantitative
physiological data provided by the HRVB device each time the participant practiced. We
collected psychometric data from the Short Form McGill Pain Questionnaire (SFMQ)
and measured performance outcomes of functional status and quality of life from the
Revised Fibromyalgia Impact Questionnaire (FIQR). We collected quantitative data
about the acceptability of HRVB using the Credibility/Expectancy Questionnaire (CEQ).
Data from the CEQ was used to explain the qualitative results obtained from focus groupdriven open-ended questions post-intervention. We evaluated PSM, the Veteran’s ability
to adhere to a treatment protocol of 20 minutes of HRVB practice twice daily. We
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evaluated PSI through the physiological measurement of HRV coherence from the
emWave2 device, as well as participant reports during the focus group discussions about
the personal experience of HRVB.
Manuscripts
This dissertation consists of three manuscripts. The first manuscript, an
integrative literature review, examined the relationship between HRVB and FM-related
chronic pain using the Theory of Symptom Self-Management. The relationship between
HRVB and FM was analyzed and evaluated based on the methodological framework
proposed by Whittemore and Knafl (45). Overall the articles in this review support that
HRVB is related to decreased pain. HRVB is a promising effective treatment for chronic
pain. However, larger randomized controlled studies are needed to evaluate the
relationship between HRVB and FM pain thoroughly.
The second manuscript details a multi-method study that examined the feasibility
of recruitment and retention of Veterans with FM. We provided quantitative data from
the emWave2 HRVB device about the feasibility of the HRVB protocol recommended by
Lehrer et al. (39). We also reported outcomes related to quality of life from the FIQR,
pain from the SFMQ, and HRV changes pre-and-post intervention.
The third manuscript is a qualitative report of the post-intervention focus group.
Eight of the ten enrolled Veterans participated in the focus group. The participants
provided rich data about their experience with HRVB, their expectations before the
intervention, and most importantly, their recommendations for future use.
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Objectives: Fibromyalgia (FM) is associated with debilitating pain and a reduced heart rate variability
(HRV), reﬂecting decreased emotional adaptability and resistance to stress. Common pharmacological
treatments are ineffective, and opioids are highly addictive and cause an estimated 15,000 overdose
deaths per year. Effective recommendations include patient-centered interventions like physical activity,
cognitive behavioral therapy, and biofeedback. Heart rate variability biofeedback (HRVB) may be effective
in improving HRV, thus increasing stress resistance and emotional adaptability and reducing pain.
Design: This integrative literature review was conducted to examine the relationship between HRVB and
FM-related chronic pain using the Theory of Symptom Self-Management and to identify available HRVB
technology.
Data Sources: We searched PubMed, EBSCOhost, and Google Scholar electronic databases for relevant
publications. Manuscripts were selected using the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses strategy, and study quality was assessed using the Critical Appraisal Skills Programme
guidelines. The relationship between HRVB and FM was analyzed and evaluated based on the methodological framework proposed by Whittemore and Knaﬂ.
Review/Analysis Methods: We reviewed 22 articles and included six in this review. Five reported HRVB as
a treatment for chronic pain, and one for FM pain.
Results: Overall, the articles in this review support the claim that HRVB is related to decreased pain. The
researchers evaluated ﬁve HRVB programs, three on handheld devices and two on desktop computers.
Conclusions: The reviewed studies had methodological ﬂaws. However, HRVB is a promising treatment
for chronic pain. Larger, randomized controlled studies are needed to thoroughly evaluate the relationship between HRVB and FM pain.
Published by Elsevier Inc. on behalf of the American Society for Pain Management Nursing

Fibromyalgia (FM), a complex chronic pain syndrome, affects 10
million individuals in the United States (Center for Disease Control,
2017). Unlike other chronic pain-related conditions, FM involves an
incoherent heart rate variability (HRV) and a dysfunctional autonomic nervous system (ANS) (Cohen et al., 2000; Dworkin & Fields,
2005; Martínez-Lavín & Hermosillo, 2000). HRV, the change in time
intervals between heartbeats, reﬂects heartebrain interaction and
ANS function (Cho et al., 2011; Kang, Chen, Chen, & Jaw, 2012; Meeus
et al., 2013; Mostouﬁ, Afari, Ahumada, Reis, & Wetherell, 2012).
When HRV is incoherent, chaotic, or insufﬁcient, ANS is also
dysfunctional, contributing to the chronic pain, decreased physical

Address correspondence to Marcelaine Reneau, MSN, FNP-BC, 388 Oak Park St.,
Summerville, SC 29486.
E-mail address: hairem@musc.edu.

functioning, and poor quality of life that are associated with ﬁbromyalgia (Cohen et al., 2000; Kang et al., 2012; Meeus et al., 2013).
Optimal or coherent HRV is associated with improved physical
functioning, improved stress regulation, improved emotional
arousal, and improved stress resistance (De jonckheere, Ibarissene,
Flocteil, & Logier, 2014; Kapitza, Passie, Bernateck, & Karst, 2010;
Lehrer & Gevirtz, 2014; McCraty & Shaffer, 2015).
Heart rate variability biofeedback (HRVB), a form of cardiorespiratory feedback training (Lehrer & Gevirtz, 2014), is a selfmanagement strategy that induces a vagal response as the individual slows their breathing rate to 4-6 breaths per minute (McCraty &
Shaffer, 2015). The decreased rate of breathing during HRVB will
induce a slower heart rate, allowing more time between heartbeats
and an improvement in HRV coherence (McCraty & Shaffer, 2015).
Additionally, repeated sessions of HRVB can sustain HRV coherence
for longer periods of time (McCraty & Shaffer, 2015). It is hypothesized that routine use of HRVB can decrease pain, improve stress

https://doi.org/10.1016/j.pmn.2019.08.001
1524-9042/Published by Elsevier Inc. on behalf of the American Society for Pain Management Nursing
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resistance and emotional adaptability, and increase overall wellbeing (Cohen et al., 2000; McCraty & Shaffer, 2015).
The purpose of this integrative literature review was to examine
studies that reported on the relationship between HRVB and FMrelated chronic pain using the Theory of Symptom SelfManagement as the theoretical framework. Additionally, we
sought to identify which HRVB technology has been used and any
comparisons among devices. However, we were able to identify only
one study devoted solely to FM-related chronic pain. To fully evaluate HRVB as a treatment for pain, we included other forms of
chronic pain in our literature review.

management and are inﬂuencing factors on self-management (Fu
et al., 2004). Fatigue or unrefreshing sleep is a hallmark symptom
of FM (Wolfe et al., 2010) and can also greatly inﬂuence selfmanagement (Cohen, 2017; Fu et al., 2004; Rosso & MaddaliBongi, 2016). Work absenteeism and disability are considered the
cause of an average of 26% of the indirect costs associated with FM
and 42% of the costs of unemployment owing to FM disability
(Chandran et al., 2012; Ghavidel-Parsa, Bidari, Amir Maaﬁ, & Ghalebaghi, 2015; Schaefer et al., 2015). Women comprise 86%-96% of
the population of FM patients and have a higher divorce rate when
compared to those suffering from other chronic pain diseases
(Wolfe, Ross, & Anderson, 1995).

Theoretical Framework
The Theory of Symptom Self-Management (TSSM) has been used
to assist individuals to reduce, prevent, relieve, or decrease the
timing of unpleasant symptoms, such as chronic pain, through selfmanagement-enhancing interventions (Fu, LeMone, & McDaniel,
2004; Hoffman, 2013), such as biofeedback (Burckhardt, 2004;
Vancleef, 2011) and HRVB (McCraty & Shaffer, 2015; Moss &
Shaffer, 2017; Wheat & Larkin, 2010). The central tenet of TSSM
that guided this review is that functional and cognitive performance
outcomes, such as quality of life and functional status, are improved
by optimizing self-directed, self-management, perceived selfefﬁcacy (PSE)eenhancing interventions, such as HRVB (Hoffman,
2013; Lorig & Holman, 2003). The key concepts of TSSM are as follows: 1) PSE for symptom self-management, 2) actual symptom selfmanagement, 3) patient characteristics, 4) symptoms, 5) performance outcomes and PSE-enhancing interventions (Hoffman, 2013).
Perceived Self-Efﬁcacy for Symptom Self-Management
Self-efﬁcacy inﬂuences how a person thinks, feels, motivates
him- or herself, and performs actions (Bandura, 1994). PSE is the
belief or conﬁdence one has in oneself to perform or execute the
actions required to produce the desired effects or outcomes
(Bandura, 1994). PSE for symptom self-management is a patient's
ability to implement speciﬁc behaviors to attain established treatment goals or desired outcomes (Hoffman, 2013).
Symptom Self-Management
Symptom self-management encompasses self-directed active
behaviors that may prevent or relieve symptoms such as pain or
decrease their frequency or intensity, allowing the patient to reach
optimal performance outcomes (Hoffman, 2013). Self-management
with biofeedback has been shown to be an effective treatment for
FM pain (Macfarlane et al., 2017). The symptom self-management
behaviors analyzed in this review are the consistent and correct
use of biofeedback. Use is considered correct if the patient engages
in HRVB as often and for as long as prescribed, following the prescribed breathing rate and depth while following along with the
electronic signals emitted by the feedback device.

Symptoms
Symptoms are the subjective experiences of a perceived threat to
health or wellness, or are signs of an undesirable outcome (Hoffman,
2013). Symptoms of FM can be diffuse and multifocal, and they can
wax and wane daily. The symptoms analyzed in this review are
chronic pain, fatigue, depression, and low HRV. FM-related pain is
often characterized as a widespread ache with multiple diffuse,
exquisitely tender muscle points (Wolfe et al., 2010).
Performance Outcomes
Performance outcomes are the effects of a person's symptom
self-management experience (Hoffman, 2013). Desired outcomes of
self-directed behaviors, such as HRVB, include decreased symptoms
of pain, depression, and fatigue, less symptom distress, and fewer
symptom occurrences (Fu et al., 2004; Hoffman, 2013). These outcomes have a direct effect on quality of life (Cohen, 2017; Fu et al.,
2004; Macfarlane et al., 2017), sleep (Cohen, 2017; Rosso &
Maddali-Bongi, 2016), and functional status (Cohen, 2017). The
performance outcomes analyzed in this review are functional status and quality of life.
Perceived Self-EfﬁcacyeEnhancing Interventions
A patient's ability to perform PSE-enhancing interventions is
developed through activity performance along with social or verbal
persuasion by others, which determines how the individual will
think, feel, self-motivate, and perform (Hoffman, 2013). The building
blocks of PSE-enhancing interventions include mastery of the activity by performing it oneself, observing others perform the activity
successfully, being persuaded by others that the activity is possible,
and perceiving one's self as possessing the strength to achieve the
goal (Hoffman, 2013). The following were analyzed in this review:
mastery of HRVB skills via observation of trainers and frequently
performing the skill oneself, being socially persuaded to perform
the activity, and self-interpretation one's HRVB skills as good or
adequate.
Methods

Patient Characteristics
Design
Patient characteristics include the physiological and psychological factors that inﬂuence outcomes and may include severity of
illness, comorbidities, age, mental state or mood status, personal
beliefs, affective reaction to illness or disease, and degrees of uncertainty (Hoffman, 2013). The patient physiological and psychological characteristics analyzed in this review are mental health
status, sleeping difﬁculties, gender, marital status, and employment
status. Depression and mood disturbance, commonly seen in FM
(Cohen, 2017; Macfarlane et al., 2017), are signiﬁcant factors in pain

This integrative review was guided by the methodological
framework proposed by Whittemore & Knaﬂ (2005). The ﬁve stages
include 1) identifying a gap in the literature about HRVB as a
treatment for FM-related chronic pain, 2) searching in the literature
for studies supporting the use of HRVB to treat FM, 3) evaluating
data using the Critical Appraisal Skills Programme (CASP) scoring
system, 4) analyzing data using the TSSM as a framework, and 5)
visually presenting a review matrix (Whittemore & Knaﬂ, 2005).
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Search Methods
In September 2017, a reference librarian at an academic medical
center was consulted to assist in ﬁnding the most appropriate
approach in searching the literature for applicable studies. The
literature was systematically selected to be included in the sample
using the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (see Fig. 1). We searched PubMed, EBSCOhost, and
Google Scholar electronic databases for relevant publications. We
searched each database for the following terms: [heart rate variability OR heart rate variability biofeedback OR heart rate coherence
biofeedback OR heart rate coherence OR biofeedback] AND [ﬁbromyalgia] AND [chronic pain]. The terms evolved from concept maps
used in the development of the aims of this review. We included
primary studies of any research design in the review. We reviewed
reference lists from included manuscripts to identify literature not
found in the initial database searches manually.
The original planned study inclusion criteria were: 1) articles
that included ﬁbromyalgia pain in the outcome measures, 2) articles reporting HRVB as an intervention, 3) peer-reviewed articles in
the English language, and 4) adult participants (>17 years). Exclusion criteria were: 1) non-FM pain, 2) literature reviews, and 3)
non-HRVB biofeedback. This search returned only one study. The
search criteria were expanded to include other forms of chronic
pain. During the review, studies involving cancer pain were eliminated; this search yielded 21 more studies. We did not set a time
limit because of the novelty of the subject matter as well as an
interest in historical ﬁndings.
Search Outcomes
The initial database searches yielded 22 articles. We removed 10
duplicates and reviewed the full text of the remaining 12 articles.
Three of the articles eliminated were literature reviews of HRVB
(Gevirtz, 2013; Moss & Shaffer, 2017; Wheat & Larkin, 2010); these
PubMed

EbscoHost

GoogleScholar

n=22

Duplicates removed
n=10

Full-text

Exclusion criteria
applied

Literature
reviews removed
n=3

Full-text read
n=9

Reviews hand
searched
n=0

Exclusion criteria
applied

Non-pain HRVB n=2
Explanatory paper
1

Articles included
n=6

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses
Statement
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were hand-searched for original studies. However, no additional
studies met inclusion criteria.
The remaining nine full-text articles were then further
assessed for eligibility, yielding six studies. Two of the articles
eliminated reported HRVB ﬁndings, but not pain treatment
(Edwards, 2014; Whited, Larkin, & Whited, 2014). The ﬁnal one
eliminated was an explanatory paper on how and why HRVB
works (Lehrer & Gevirtz, 2014). A review of reference lists of the
selected articles and the previous literature reviews did not yield
any additional studies.
Data Presentation
The resulting data were categorized and presented in table form
(Table 1) by reference, interventions, biofeedback technology,
population, study design, outcome measures, relevant ﬁndings, and
grading. The Critical Appraisal Skills Programme (CASP) guided the
grading of each randomized controlled and cohort study by
addressing three broad questions: 1) Are the results of the study
valid? 2) What are the results? and 3) Will the results help locally?
(Critical Appraisal Skills Programme, 2018).
Results
Overview of Studies
The six articles reviewed consisted of three randomized pilot
ele, Melin, &
studies (Berry et al., 2014; Hallman, Olsson, von Sche
Lyskov, 2011; Weeks, Whitney, Tindall, & Carter, 2015) one nonrandomized pilot study (Hassett et al., 2007), one retrospective
archival study, (Wilson, 2017), and one retrospective cohort study
(Soer, Vos, Hofstra, & Reneman, 2014). The independent variable
was HRVB in all studies. The study by Hassett et al. (2007) was the
only one which treated FM-related pain solely with HRVB. Hallman
et al. (2011) compared two forms of treatment for neck and
shoulder pain. Patients in the ﬁrst group received multiple sessions
of HRVB, whereas those in the second group received the same
breathing protocol instructions during session one but did not
receive instructions on breathing during the remaining sessions.
Berry et al. (2014) added HRVB to standard care for chronic pain;
however, they did not specify what this care entailed or speciﬁcs
about pain location. However, they did exclude individuals with
diabetes or traumatic musculoskeletal system damage. Soer et al.
(2014) added HRVB to Back School, a personalized pain rehabilitation program designed to increase physical capacity and cognitive
behavior interventions for chronic back pain. Weeks et al. (2015)
compared faded HRVB to full HRVB in nine sessions to treat nonmalignant chronic musculoskeletal pain, ﬁbromyalgia, headache,
neuropathy, and reﬂex sympathetic dystrophy over a 3-week
period. Faded HRVB consisted of visual feedback during session 1,
followed by a systematic reduction of visual biofeedback with each
session so that by session nine, the participants were controlling
HRV without visual feedback. The control group received visual
biofeedback for nine sessions. Wilson (2017) included individuals
with neuropathic pain, musculoskeletal pain, and headache. The
primary outcomes measured were pain (n ¼ 6), functional status
(n ¼ 5), depression (n ¼ 3), HRV (n ¼ 4), catastrophizing (n ¼ 1),
sleep (n ¼ 1), anxiety (n ¼ 1), somatization (n ¼ 1), self-reported
health status (n ¼ 1), and biofeedback skills (n ¼ 1). Only three
studies reported study controls: standard care (n ¼ 1), Back School
(n ¼ 1), and full HRVB (n ¼ 1). Although none of the studies or
reviews articulated the use of any theoretical framework or model,
we identiﬁed some of the TSSM constructs in some of the studies
(see Table 2).
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Table 1
HRVB Literature Review Outcomes
Reference

Intervention

Biofeedback
Technology

Population

Design

Outcome Measures

Relevant Findings

CASP Score

Wilson. (2017)

Heart rate
variability
biofeedback
(HRVB)

N ¼ 72; 56 F;
15 M; 1 TG

Retrospective
archival study
(not randomized)

Pain,
catastrophizing,
depression, anxiety,
somatization

Decreased pain
p < .001, however
not sustained
across sessions

n/a

Hassett, Radvanski,
Vaschillo,
et al. (2007)

HRVB

“Relaxing
Rhythms” from
Unyte Health Inc.
ﬁnger sensor
measuring skin
conductance levels
and HRV
J&JJ-330 unit on
computer screen
and
Cardiosignalizer
CS-03 handheld
device

N ¼ 12;
12 F

Pilot (not
randomized)

Functional status,
depression, pain,
sleep

n/a

Soer, Vos, Hofstra,
& Reneman.
(2014)

HRVB and
mindfulness
exercises added
to Back School

Freeze-frame by
Heart Math, visual
biofeedback on a
computer screen

N ¼ 170;
71 F; 99 M

Pain, pain disability,
self-reported
health status, HRV

Berry, Chapple,
Ginsberg,
Gleichauf,
Meyer, &
Nagpal. (2014)

HRVB plus
standard care

N ¼ 14;
1 F; 13 M

Hallman, Olsson,
von Scheele,
Melin, Lyskov.
(2011)

HRVB

Quick Coherence,
controlled
breathing and selfinduction of
positive or neutral
emotional state
J&JJ-330-2 visual
handheld device

A retrospective
cohort study
comparing the
intervention to
Back School alone
Randomized Pilot
comparing the
intervention to
standard care

N ¼ 24;
21 F

Randomized Pilot
comparing
intervention to
standard care

Pain, HRV, physical
function,
depression, vitality,
social function

Weeks, Tindall,
Carter.(2015)

Faded HRVB

N ¼ 20;
5 F; 6 M

Randomized Pilot
comparing the
intervention to full
HRVB

HRV, use of BF
skills, pain,
functional status,
kinesophobia

Decreased pain
p ¼ .455 after 10
sessions, p ¼ .006
after 3 months;
increased
functional status
p ¼ .069 after 10
sessions, p ¼ .0022
after 3 months
Increased HRV
p < .01; decreased
pain p ¼ .15;
increased function
p ¼ .02
Increased HRV
191% p ¼ .04;
decreased pain 36%
p < .001; decreased
physical limitations
42% p < .001
Increased resting
HRV, increased LF
HRV p ¼ .016
interaction effect,
no signiﬁcant HF
HRV interaction
effect; decreased
pain p ¼ .049;
decreased physical
function p ¼ .27;
decreased
depression p ¼ .78;
increased vitality
p ¼ .005; increased
social function
p ¼ .047
HRV no signiﬁcant
difference between
groups; decreased
pain p ¼ .291 (no
difference from the
control group),
improved
functional status
p ¼ .464 (no
difference
compared to
control group),
decreased
kinesophobia
compared to
control group
p ¼ .102, improved
HRVB used p ¼ .132
compared to
control group

Freeze-frame by
Heart Math, visual
biofeedback on a
computer screen

Pain, HRV, physical
activity limitations

8

9

10

10

BF ¼ biofeedback; F ¼ female; HRV ¼ heart rate variability; HRVB ¼ heart rate variability biofeedback; M ¼ male; T ¼ transgender.

Perceived Self-Efﬁcacy-Enhancing Interventions
Observation
The participants in all studies were instructed and coached by
HRVB-trained clinicians or researchers on how to correctly use the
respective HRVB device (Hallman et al., 2011; Hassett et al., 2007;

Soer et al., 2014; Weeks et al., 2015; Wilson, 2017). The authors did
not indicate how these instructions affected the study outcomes.
Frequency
The participants practiced HRVB in weekly sessions that ranged
from 10 weeks (n ¼ 2) to 6, 5, and 3 weeks (Berry et al., 2014;
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Table 2
Theory of Symptom Self-Management Concepts Included in Studies
Self-Management
Concepts
Patient
characteristics
Age
Gender
Mental health
status
Sleep quality
Marital status

Employment status

PSE interventions
Observation
Frequency

Verbal or social
persuasion
Self-interpretation
of HRVB skills
Symptoms
Pain severity
Fatigue
Depression
Low HRV
Symptom selfmanagement
Correct use of
HRVB
Consistent use of
HRVB
Performance
outcomes
Functional status
Quality of life
X reported
:indirectly reported
NR not reported

Wilson (2017)

Hassett et al. (2007)

Soer et al. (2014)

Berry et al. (2014)

Hallman et al. (2011)

Weeks et al. (2015)

18-78
56 F; 15 M; 1T
NR

18-60
12 F
NR

Mean 44
71F; 99 M
NR

Adult
1M; 13F
NR

Mean 42
21 F
NR

Mean 58
5 F; 6M
NR

NR
28 Married; 2
signiﬁcant other; 23
single; 16 divorced;
2 separated;
28 Employed; 30
disabled; 7
unemployed; 7
retired

NR
NR

NR
NR

NR
NR

NR
NR

NR
NR

NR

NR

NR

NR

6 Employed; 5
unemployed

X
More than 3 clinic
sessions

X
6 Weekly clinic
sessions

X
4 In clinic
session

NR

NR

X
10 In clinic session;
home practice
15 minutes daily,
5 days/week
NR

X
3 Times a week for
3 weeks in clinic
sessions

Verbal

X
10 Weekly clinic
sessions; home
practice 20 min.
twice a day
Verbal

NR

Light display

Light display

Light display

Light display

Light display

Light display

X
NR
NR
NR

X
:
NR
X

X
NR
:
X

X
NR
:
X

X
NR
X
X

X
NR
NR
X

NR

NR

NR

NR

NR

X

NR

NR

NR

NR

NR

X

NR
NR

:
:

NR
X

NR
NR

NR
X

NR
NR

F ¼ female; HRV ¼ heart rate variability; HRVB ¼ heart rate variability biofeedback; M ¼ male; NR ¼ not reported; T ¼ transgender.

Hallman et al., 2011; Hassett et al., 2007; Soer et al., 2014; Weeks
et al., 2015; Wilson, 2017). Sessions lengths varied, ranging from
10 minutes (n ¼ 2) to 20 minutes (n ¼ 1) to 45-60 minutes (n ¼ 1) to
a full hour (n ¼ 1). Berry et al. (2014) did not provide the length of
time per session. Hassett et al. (2007) and Hallman et al. (2011)
added recommendations for daily home practice, 20 minutes
twice daily and 15 minutes 5 times a week, respectively.
Verbal or Social Persuasion
Hassett et al. (2007) and Wilson (2017) reported additional
verbal coaching to improve respiration rates and prevent participant hyperventilation. None of the study participants had the opportunity to observe their peers using HRVB.
Self-Interpretation of HRVB Skills
PSE can be enhanced when individuals are able to self-interpret
skill mastery. All the HRVB devices reviewed provided visual feedback that allowed the participants to track HRV coherence while
they breathed at the prescribed rate and depth. The Relaxing
Rhythms training program displayed an image of a staircase on a
screen when HRV was coherent and disappeared when incoherent;
as the participant advanced in skill level and continued with optimal
HRV, the staircase evolved into a bridge (Wilson, 2017). Blinking

lights advanced from red (no synchronization) to blue (advancing
synchronization) to green (optimal synchronization) on the emWave
desktop HRVB program (Heart Math, 2004). The J&J I-330 HRVB
device projected a light display onto a computer screen that moved
up as the target respiratory frequency was achieved, and down as the
target was lost (J&J Engineering). Only Soer et al. (2014) reported
that the participants were required to demonstrate basic HRVB skill
before they were able to use HRVB during stress-inducing events.
The participants in the Hassett et al. (2007) study reported that the
HRVB device was easy to use, and that they beneﬁted from the
biofeedback training and would recommend the treatment to
others. None of the other studies provided anecdotal reports or
qualitative data about the participants’ self-reported experiences
with HRVB.
Patient Characteristics
The ratio of women to men in the studies reviewed was almost
2:1 (62:36), and only 1 transgender individual was included. Soer
et al., (2014) linear regression analysis did not report any signiﬁcant relationship between a change in HRV coherence score and
gender. The remaining studies did not report a relationship between gender and measured outcomes.
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Depression, anxiety, and negative moods were outcomes
measured in most of the studies (Berry et al., 2014; Hallman et al.,
2011; Hassett et al., 2007; Soer et al., 2014; Wilson, 2017). However, none of the studies reported how mental health status might have
affected pain. Only Hassett et al. (2007) reported sleep quality. They
administered the Pittsburg Sleep Quality Index, a 19-item self-rated
questionnaire, and reported improved sleep quality (p ¼ .0148) that
was not sustained at the 3-month postintervention follow up.
Wilson (2017) was the only researcher to report marital status:
28 married, 2 with signiﬁcant others, 23 single, 16 divorced, and 2
legally separated participants. There was no reported association
between marital status and HRV outcomes.
Employment status was only reported in two studies (Weeks
et al., 2015; Wilson, 2017). Most individuals were either employed
(n ¼ 34) or disabled (n ¼ 30); the remaining participants were
unemployed (n ¼ 12) and retired (n ¼ 7). Neither author reported
how employment status might have affected the outcomes.
Symptoms
The symptoms of ﬁbromyalgia covered in this review are pain,
fatigue, depression, and HRV. Methods of pain measurement varied
greatly between each study and are detailed in Table 1. Most studies
reported a statistically signiﬁcant reduction in pain with HRVB
(Berry et al., 2014; Hallman et al., 2011; Soer et al., 2014; Weeks
et al., 2015; Wilson, 2017). However, there was no statistically
signiﬁcant difference in pain reduction between the treatment and
control groups (p ¼ .049, p ¼ .15) in the two RCTs (Hallman et al.,
2011; Soer et al., 2014). Hassett et al., (2007) reported that
although pain reduction was not statistically signiﬁcant (p ¼ .0455),
it was sustained at the 3-month follow-up (p ¼ .006).
Only one study measured fatigue as an outcome. Hassett et al.
(2007) administered the Fibromyalgia Impact Questionnaire (FIQ),
a 19-item self-reported questionnaire designed to measure fatigue
among other physical impairments, and reported an improved FIQ
score (p ¼ .0686) at the end of session 10 compared to session 1,
which was sustained at the 3-month follow-up (p ¼ .0022).
Overall depression scores were decreased after HRVB (see
Table 1; Berry et al., 2014; Hallman et al., 2011; Hassett et al., 2007;
Soer et al., 2014). Soer et al. (2014) reported improved self-rated
mental health scores in the HRVB group (p ¼ .38), but they were
not statistically different from those of the control group (p ¼ .39).
HRV changes were reported in all but one of the studies. Overall,
there was a statistically signiﬁcant improvement (p < .01-p ¼ .023)
in HRV coherence (see Table 1).
Symptom Self-Management
Weeks et al. (2015) reported that participants in the faded HRVB
group demonstrated improved use of unassisted biofeedback after
three weeks of practice of faded visual feedback compared to full
visual HRVB training. The researchers concluded that faded HRVB
improved biofeedback skills because the participants were able to
optimize their HRV without the use of HRVB at the end of the study.
Performance Outcomes
Functional status and quality of life were measured by Hassett
et al. (2007) with the FIQ. In their study, FM patients reported
improved scores (p ¼ .0686) on the FIQ after HRVB training, which
were signiﬁcantly sustained (p ¼ .0022) 3 months postintervention
(Hassett et al., 2007). Hallman et al. (2011) and Soer et al. (2014)
administered the SF-36, a 36-item questionnaire designed to

assess health-related quality of life. They reported improved
physical functioning, improved vitality, and improved social functioning after HRVB training.
HRVB Technology
The HRVB technology across all studies used visual biofeedback
projected onto a screen. Freeze Frame, manufactured by HeartMath, was used in two studies (Soer et al., 2014; Weeks et al., 2015).
The J&JJ-330 unit, a visual handheld device, was used by Hassett
et al. (2007) and Hallman et al. (2011). Wilson (2017) used Relaxing Rhythms from Unyte Health, Inc. None of the authors provided
reliability or validity data to support the results. None of the authors reported any contraindications to using HRVB. However,
some did report participant use of beta blockers and a diagnosis of
coronary artery disease as an exclusion criterion (Berry et al., 2014;
Hallman et al., 2011; Soer et al., 2014).
Discussion
The purpose of this review was to examine the relationship
between HRVB and FM-related pain through the lens of the TSSM
and to identify the HRVB technology used to treat FM pain. However, as discussed earlier, we included studies of chronic musculoskeletal pain. When pain management was evaluated against the
central tenet of TSSM, that functional and cognitive patient outcomes are improved by enhancing self-directed and selfmanagement behaviors, signiﬁcant gaps were identiﬁed.
PSE-Enhancing Interventions
Interventions that include self-management skills support selfefﬁcacy and improve self-care (Fu et al., 2004). Lehrer et al. (2013)
developed a protocol and manual for HRVB training and recommended ﬁve in-ofﬁce sessions for participant instruction and home
practice 20 minutes twice daily for 3 months, followed by 20minute practice sessions every 2-3 days to maintain beneﬁts. The
frequency and duration of HRVB practice reported in this review
were inconsistent, making it difﬁcult to determine how much
practice is ideal for skill mastery and optimal outcomes. The researchers and clinicians taught the participants how to use HRVB;
however, we do not know how this affected the outcomes or if the
participants truly understood the instructions.
Patient Characteristics
Physiological, psychological, and contextual patient characteristics signiﬁcantly inﬂuence performance outcomes such as quality
of life and functional status (Hoffman, 2013; Iversen, 2003).
Although FM patients are more likely to suffer from depression and
sleep disturbances than those with other chronic pain disorders
(Cohen, 2017), the studies reviewed did not include these variables.
The studies reviewed did include sex as a variable but did not report
how this may have affected the outcomes. The female-to-male ratio
of FM sufferers in the general population is 2:1; however, the
female-to-male ratio was almost 1:1 in the studies reviewed. This
review thus may not be an accurate representation of FM patient
outcomes. Psychosocial issues like marital status and employment
status may contribute to FM symptoms (Cohen, 2017) and are
associated with increased divorce rates (Wolfe et al., 1995); nevertheless, these factors were underrepresented and their signiﬁcance
was not discussed in the studies reviewed.
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Symptoms

Strengths and Limitations

Overall, there was a statistically signiﬁcant reduction in pain
after HRVB compared to control groups in all but one study, supporting the current recommendations for patient-centered nonpharmaceutical pain treatment (Babu, Mathew, Danda, & Prakash,
2007; Cohen, 2017; Gevirtz, 2013) and self-management
enhancing interventions (Fu et al., 2004; Hoffman, 2013). However, sustained pain reduction was evaluated in only two of the six
studies and seen in only one 3-month follow-up study. Four of the
studies demonstrated a statistically signiﬁcant increase in HRV, but
this did not translate into decreased pain, increased resilience,
improved emotional state, or improved stress resistance. None of
the studies discussed pharmacological treatment or its effects on
pain. Sleep disturbance and fatigue are known triggers for FM pain
(Clauw, 2014; Wolfe et al., 2010) and should be included as outcomes in future studies. Overall, mood improved with HRVB.
Depression scores decreased (Hallman et al., 2011; Hassett et al.,
2007), negative mood improved (Berry et al., 2014), and self-rated
mental health scores increased, indicating improved mental
health (Soer et al., 2014).

There were several limitations in this review. First, the pilot
studies were small and not guided by power analyses; second, the
larger studies were retrospective non-randomized controlled trials.
None of the studies compared HRVB to sham or other biofeedback.
Second, only one of the studies was on FM exclusively, so other
chronic pain studies were included, although it has been established
in the literature that the pain caused by FM is different from that of
other disorders (Clauw, 2014; Wolfe et al., 2010). None of the studies
evaluated stress resistance, a marker of optimal HRV and a functional
ANS (Cho et al., 2011; Kang et al., 2012; Meeus et al., 2013; Mostouﬁ
et al., 2012). Additionally, no qualitative or mixed-method studies
were identiﬁed. Such studies could enhance our knowledge of the
effects HRVB may have on chronic pain, quality of life, and functional
status. Lastly, we did not search the literature for different biofeedback devices; this may have yielded additional studies.

Symptom Self-Management
HRVB is designed to provide patients with a self-directed active
behavior to self-manage pain. Once the patient has demonstrated
adequate HRVB skills in the clinic setting, he or she may receive a
prescription from the clinician for home use. The patient can then
self-determine the correct use of HRVB by following the prompts
from the device. Consistent and correct use of the HRVB training
device can allow the patient to self-manage his or her pain. Clinicians can verify consistent and correct use outside of the clinic
setting by reviewing the reports generated by the software of the
HRVB device. However, only one study, Weeks et al. (2015) reported
that participants who used HRVB at the prescribed frequency reported decreased pain postintervention.
Performance Outcomes
Functional status and quality of life are the performance outcomes evaluated in this review. Again, Hassett et al. (2007), the only
study involving FM patients, measured outcomes with the FIQ. The
FIQ is a reliable instrument used to measure quality of life and
functional status (Iversen, 2003). Although the researchers reported improved scores, the improvement was not statistically
signiﬁcant. However, Soer et al. (2014) and Hallman et al. (2011)
administered the SF-36, a questionnaire that measures quality of
life by evaluating self-report of physical function, vitality, and social
function. Both studies reported an increase in these measures postHRVB intervention. These instruments would be appropriate for
future studies.
HRVB Technology
This review demonstrated that there are several biofeedback
devices available on the market for HRV modulation. The authors
did not provide reliability or validity data about the HRVB devices,
making it challenging to support their use in future studies. The
monetary cost of the devices was not given, and there was no
discussion of software or device problems reported during the
study. Although there was no discussion of any contraindication to
HRVB, it can be assumed that participants with coronary artery
disease could face risks from HRVB.

Conclusion
FM is a debilitating, painful condition affecting 2% of the population (Wolfe et al., 1995) with relatively few effective treatments
available (Macfarlane et al., 2017). Current recommendations for
FM treatment by the European League Against Rheumatism and the
Canadian Pain Society include non-pharmacological therapies such
as biofeedback (Clauw, 2014; Macfarlane et al., 2017). Although
HRVB is a promising treatment modality for chronic pain, only one
study was found that evaluated the relationship between HRVB and
FM pain (Hassett et al., 2007). Future research is needed to thoroughly evaluate the relationship between FM and HRVB.
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Feasibility and Acceptability of Heart Rate Variability Biofeedback in a Group of Veterans with
Fibromyalgia
Abstract
BACKGROUND: Fibromyalgia (FM) is characterized by diffuse pain, fatigue, sleep
disturbance, and depression leading to decreased functional status and poor quality of life
(QOL). Research suggests that autonomic dysfunction and diminished heart rate variability
(HRV) may explain some symptoms of FM. The purpose of this study was to determine
feasibility and acceptability of heart rate variability biofeedback (HRVB) to treat FM.
METHODS: We enrolled 10 Veterans for 8 weeks of HRVB training to determine the feasibility
to adhere to a recommended HRVB protocol and to examine acceptability and satisfaction with
the intervention. They were taught how to use the emWave2 biofeedback device and asked to
practice with the device at home twice daily for 20 minutes. We collected data from the device to
evaluate their ability to adhere to the treatment protocol. Data collected at sessions 2-8 provided
a signal of efficacy from HRVB for pain control, heart rate coherence, functional status, and
QOL.
FINDINGS: Most Veterans believed HRVB is a viable treatment for FM that will reduce pain
by 50-80%. Data suggest a twice-daily HRVB practice protocol is not feasible. However, once
daily 20-minute HRVB home sessions were feasible and acceptable to study participants. HRVB
contributed to an improvement in functional status and QOL within our sample.
CONCLUSION: It appears that although a twice-a-day HRVB practice protocol is not feasible,
when Veterans did practice once daily, 20-minute HRVB sessions were acceptable. HRVB may
be an effective strategy to improve functional status and QOL for Veterans with FM.
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Introduction
Fibromyalgia (FM) is a complex, painful condition with predominant symptoms of pain,
fatigue, depression, and sleep deprivation that lead to a significant decrease in functional status
and diminished quality of life (1). Individuals with FM often report symptoms that are variable
and unpredictable, leading to frustration and often feeling as if family members, friends, and
health care providers do not believe them (2, 3).
The fatigue, memory problems, cognitive impairment, and functional limitations
associated with FM (4, 5) contribute to 1-2% loss of national U.S. productivity (6, 7), and $12-14
billion per year in national health care costs (6). The Department of Veterans Health
Administration (VA) and Department of Defense (DoD) recognize FM as an illness potentially
linked to injuries and exposures sustained during the Persian Gulf War (8).
The DoD and VA have linked FM to the physical and emotional trauma sustained by
service members who deployed during wars in the Persian Gulf and in Afghanistan, as well as to
the various natural and artificial environmental exposures in that region (9). Individuals
diagnosed with FM have a higher prevalence of traumatic events such as those experienced in
combat and in physical and sexual abuse (10, 11). Repetitive muscular injuries are attributed to
service members carrying over 80 pounds of equipment daily for 6-12 months during multiple
deployments, which has resulted in more than 50% of service members/Veterans returning from
these conflicts reporting chronic pain not related to direct injuries such as shrapnel, gunshots, or
blasts (9, 12, 13). The FM cost to the military health care system in 2006 was $105.6 million,
with an average individual cost of $12,472; this is five times higher than the utilization costs on
non-fibromyalgia diagnosed military beneficiaries (14). The incidence of FM diagnosis and FMrelated disability in the VA system is rising at an alarming rate (14).
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The American College of Rheumatology has set the FM diagnostic criteria (5). FM
diagnosis is satisfied with one of the following 3 conditions: 1) the Widespread Pain Index
(WPI) ≥ 7, the Symptom Severity Score (SS) ≥ 5, or the WPI = 36 and the SS ≥ 9; 2); symptoms
are present and at a similar level for at least 3 months; or 3) the patient lacked a disorder that
would otherwise explain the pain (5).
Pathophysiology of FM
Research utilizing functional magnetic resonance imaging (fMRI) demonstrates that
among individuals with FM, there is a disruption of the pain network connectivity (15).
Strengthened connectivity of the brain regions involved in processing and reducing connectivity
of the regions involved in pain inhibitory modulation may explain this widespread chronic pain
(15). The default mode network (DMN), a constellation of brain regions engaged in selfreferential thinking, is disrupted in FM during tasks like visual attention and cognitive attention,
which may explain symptoms of memory problems and cognitive impairment (16, 17). An
abnormally increased level of connectivity between the DMN and the insular cortex may also
explain higher reported pain levels (17). Additionally, a dysfunction of the cardiac autonomic
nervous system (ANS), characterized by higher sympathetic and lower parasympathetic cardiac
autonomic modulation, is associated with diminished heart rate variability (HRV) and is related
to the impact of FM on quality of life (18, 19).
Heart Rate Variability
Heart rate variability (HRV) is the time measurement of the oscillations of the R-to-R
intervals (20-22) and reflects heart-brain interaction and the ANS (21, 23). HRV reflects the
activity of the sympathetic and parasympathetic nervous systems providing information on how
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the systems interact and function as a whole (24). Thus, analyzing HRV provides quantitative
information about the state of the ANS (19).
HRV is measured on spectra analysis via high frequency (HF) (0.15-0.40 Hz) and low
frequency (LF) (0.04-0.15) bands. The LF is influenced by sympathetic activities like significant
psychological and physiological activities, and parasympathetic conditions of slow breathing (6
breaths per minute) (25). Optimal HRV, cardiac coherence, is an ordered, harmonic cardiac
pattern reflecting positive emotions and a general sense of well-being (23). Low HRV, cardiac
incoherence, reflects decreased resistance to stress, anxiety, and decreased emotional adaptability
(19, 21, 23, 26), factors known to exacerbate chronic pain. Self-regulation techniques that
increase HRV coherence can reduce pain, improve physical activity, and improve cognitive
function (23).
Treatment Recommendations
The ANS dysfunction and diminished HRV associated with FM are generally not
demonstrated in chronic musculoskeletal pain; thus, comparing treatment between these pain
syndromes is challenging (5, 19). The most commonly used guidelines for FM treatment are
from the European League Against Rheumatism (EULAR) 2008, revised in 2016, American Pain
Society (APS) 2005, German Association of the Scientific Medical Societies (AWMF) 2013,
Israeli Pain Society (IPS) and Canadian Pain Society (CPS) (1, 27). There is a consensus among
the EULAR, APS, AWMF, IPS, and CPS guidelines that effective treatment must include a
multidisciplinary approach that prioritizes nonpharmacological treatments, offers judicious
pharmacological treatments (1, 27), and reflects the biopsychosocial model (1) which integrates
biological, psychological and social factors into the treatment plan (28). The most recent
VA/DoD Clinical Practice Guidelines for the treatment of chronic pain, which includes pain
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related to fibromyalgia, are to utilize cognitive behavioral therapy, biofeedback, exercise,
multidisciplinary psychosocial rehabilitation (4, 29), physical therapy, occupational therapy,
acupuncture, spinal manipulation, and/or complementary and alternative medicine (1, 12).
Unlike chronic musculoskeletal pain, FM treatment must improve autonomic function, optimize
HRV, and improve pain network connectivity through the DMN (17, 30).
Heart Rate Variability Biofeedback
Heart rate variability biofeedback (HRVB) enables self-regulation by using technology to
guide deep breathing at an average rate of 6 breaths per minute. This deep breathing is an
autonomic maneuver that may intensify the interaction between autonomic and nociceptive
pathways (18). HRVB induces HRV coherence (HRC) and ANS regulation through the
activation of baroreceptors in the vagus nerve (18, 23, 31-34). Repeated sessions of HRVB can
sustain improved HRC and, with sufficient practice, can be used by individuals before, during, or
after times of increased stress or adversity, thus optimizing stress resistance and emotional
adaptability to decrease pain and increase overall well-being (23, 31, 32).
The purpose of this study was to determine the feasibility and adherence to a
recommended HRVB protocol using a handheld training device (emWave2) that objectively
monitors HRV and displays the physiological level of HRC among Veterans with FM.
Additionally, we examined the feasibility of recruitment and retention of Veterans diagnosed
with FM, along with acceptability and satisfaction with HRVB. Finally, we collected data related
to HRC, qualities of pain, and FM symptoms, including overall function and QOL, as an initial
signal of the efficacy of HRVB.
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Theoretical Foundation
The theory of symptom self-management (TSSM) was used to guide this study. TSSM is
effective in assisting individuals in reducing, relieving, or decrease the frequency and duration of
pain, through the use of self-management enhancing interventions like biofeedback (35, 36). The
central tenet of TSSM is that when self-directed, self-managed, perceived self-efficacyenhancing interventions (PSI) such as HRVB are optimized, cognitive performance outcomes,
such as quality of life and functional status, are improved (36, 37). Additionally, cognitive
behavioral strategies, like HRVB, improve self-efficacy and shift the individual’s perception of
helplessness to a sense of ability to self-improve (38).
Methods
Investigator HRVB Training
The Principal Investigator (PI) completed the HeartMath® Interventions Certification
Program for Health Professionals (39), designed for physicians, advanced practice nurses, and
other health professionals who want to add HRVB techniques to their practice prior to study
implementation. The program consists of six 90-minute live and recorded webinars, home study,
and video presentations.
Participants/Recruitment
This feasibility study was not designed to test a hypothesis, and there was no plan to
report inferential statistics. We based the sample size on the pragmatics of recruiting from the
VA, patient flow, and budget constraints around the purchase of the emWave2 HRVB devices
(40). Additionally, there are no concrete recommendations for sample size in a feasibility study;
however, we may achieve the aims of the study with a sample of 10 participants (41) (Table 1).
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This study was approved by the Medical University of South Carolina Institutional
Review Board (IRB) and the Ralph H. Johnson VA Medical Center Research and Development
Board. We placed IRB-approved recruitment flyers in the lobbies and exam rooms of primary
care and mental health clinics of a southeastern United States VA health center. We also gave
flyers to the primary care providers, mental health providers, and nurses in these clinics.
Additionally, we attended the monthly meeting for clinic staff and provided information and time
for questions and answers about the planned study. The health care providers and medical staff
were not involved in the study and did not receive any finders’ fees.
Inclusion criteria included male and female Veterans ages 18 and older with a
documented diagnosis of fibromyalgia. Veterans of all races and ethnicities were eligible to
participate. Exclusion criteria were any major cardiovascular disease, current use of medications
that regulate heart rate, major pulmonary disease, a major psychosis diagnosis, self-reported
pregnancy, or prior experience with HRVB. Study participants received a $5 gift card during
each visit.
Design
We used a multi-method design to inform the following questions: 1) Is it feasible to
recruit and retain Veterans from a VA on the southeast coast of the United States in a study
implementing HRVB to treat FM-related chronic pain? 2) Is it feasible for Veterans to adhere to
the recommended HRVB protocol? and, 3) Will Veterans find this intervention acceptable?
Procedures
Consistent with prior studies and recommendations from the developers of the emWave2
(32, 42-44), we conducted an initial feasibility trial of HRVB practice 8 once-weekly one-hour
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individual sessions with each participant. After participants provided informed written consent,
we proceeded with the initial study visit.
Initial Visit
During the initial visit, the participants provided demographic data, completed the
Credibility/Expectancy Questionnaire (CEQ), Revised Fibromyalgia Impact Questionnaire
(FIQR), and Short form McGill Pain Questionnaire (SFMQ). Each participant received an
emWave2 handheld device, USB connector, ear sensor, quick start guide, and practice plan to use
in the clinic and to take home for practice. We demonstrated the proper use and care of the
device, including how to clip the enclosed photoplethysmograph (PPG) sensor on the
participant’s ear. Participants were shown features on the device, such as a blinking blue light
that indicated the reading of the participant’s pulse. The study team assisted with the
configuration of initial settings to default level 1 (low) using the Quick Start Guide included in
the box. The participant was provided time to practice HRVB during the initial visit, which
included being able to see a rising and falling light in the Heart Action Strip with each breath,
indicating heart rhythm and HRC. The participant was instructed to take slow rhythmic breaths.
The goal was to increase HRC and change the coherence level indicator from red (low
coherence/baseline) to blue (medium coherence/ improving), to green (high coherence/optimal),
and to remain in the green zone as long as possible during the 20-minute practice session.
Additionally, based on the protocols used by Lehrer et al. (45), participants were instructed to
practice with the device at home for 20 minutes twice daily. We provided the participants with a
phone number to call if they had any difficulty with the device in between study visits.
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Visits 2-8
During visits 2-8, participants completed the SFMQ and the FIQR. We downloaded and
stored the physiological data from the participant’s emWave2 and discussed the results with each
participant. We discussed any problems with the device or barriers to practicing as
recommended. We discussed strategies to overcome practice barriers and to troubleshoot any
technical difficulties. Participants practiced on their emWave2 devices for 20 minutes during
each visit and received additional breathing technique coaching as needed.
Variables and Their Measures
We collected standard demographic data during the initial visit: age, gender, race,
ethnicity, education level, employment status, mental health history, and marital status. We also
asked about the frequency of aerobic physical activity, strength training, and stretching per week.
See Table 1 for demographic data.
We measured treatment outcomes expectancy and credibility with the CEQ at the initial
visit to assess HRVB as a perceived method of FM symptom management (46). Four CEQ
questions ask if individuals expect treatment to improve their symptoms (expectancy), and two
questions ask about treatment believability and logic (credibility) (46, 47). The CEQ has 2 rating
scales, 1 to 9 (not at all to very much) and 0% to 100 % (not at all to very much). Percentage
ratings are transformed linearly to a scale of 1 to 9 (minimum to maximum), allowing for a sum
score ranging from 3 to 27 (minimal to maximum credibility and expectancy) (47). In previous
studies, treatment expectancy has correlated higher with treatment outcomes than treatment
credibility (46, 47). There is a high internal consistency of the expectancy factor (Cronbach’s α
between 0.79 and 0.90), the credibility factor (Cronbach’s α 0.81 and 0.86), and a standardized α
of 0.84 to 0.85 for the whole scale (both factors) (46).
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We assessed the sensory and affective quality of pain with the Short-form McGill Pain
Questionnaire (SFMQ). The SFMQ consists of 11 sensory and 4 affective descriptors of pain
(48). Each word is scored on a 4-point ordinal scale and totaled for a Pain Rating Index of 0 to
45 (no pain to severe pain) (48). When the SFMQ was used with FM patients, Cronbach’s alpha
was estimated at α = 0.73-0.89, and test-retest reliability ranged from 0.45-0.73 for one- and
three-month intervals (49). The SFMQ moderately correlated with the Western and Ontario and
McMaster Universities Osteoarthritis Index and the Short Form 36 Health Survey bodily pain
scales (r=0.36 and -0.36 respectively; p <0.01) in 200 patients with hip and knee osteoarthritis
(50).
Participants also were asked to complete the FIQR at the start of each visit. The FIQR
consists of 21 questions that are divided into 3 domains: function, global impact, and FM-related
symptoms in the past 7 days (51). Questions are rated on a 0 to 10 numeric scale, with a better
quality of life being a lower total FIQR score (51). The Cronbach’s alpha coefficient measures in
the 3 domains were 0.90 for function, 0.81 for overall impact, and 0.89 for the severity of
symptoms (52). The FIQR was closely correlated with the Fibromyalgia Impact Questionnaire
(r=0.69 to 0.88, p< 0.01) (51). The 3 domains in the FIQR also closely correlated with the 36Item Short Form Health Survey: function (r= -0.26 - -0.80), global impact (r= -0.30 - -0.64), and
symptoms of FM (r= -0.43 - -0.66) (51).
Computer software calculated HRC as the ratio between low frequency (LF) HRV
divided by the sum of the high frequency (HF) and LF (53). The resulting average weighted
score ranged from 0 to 200 (low coherence to high coherence) (53). We collected and recorded
the HRC scores, session duration, session frequency, and heart rate from the emWave2 at each
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study visit. Data, including practice frequency and time spent using the emWave2 device, were
downloaded into the HeartMath software and reviewed with the participant at each study visit.
Results
Participant Characteristics
We enrolled 7 women between the ages of 33 and 68 years (mean=52) and 3 men
between the age 33 and 54 years (mean =47). Participants were white (n=5), African American
(n=4) or Hispanic (n=1). All had at least some higher education (Table1). Only 3 participants
were employed. All participants had a mental health diagnosis, including depression (n=6),
anxiety (n=2), and/or post-traumatic stress disorder (PTSD) (n=4). Most were married. Fifty to
60% of the Veterans self-reported that they never exercise (Table 2).
Table 1. Participant demographics and baseline history

Gender
Female
Male
Race/ethnicity
White
African American
Hispanic
Education
High school/GED
Partial college
College degree
Graduate level
Employment
Unemployed
Fulltime
Medically disabled
Working
Unable to work
Retired
Mental health
Depression

Number

Percent

7
3

70
30

5
4
1

50
40
10

10
3
4
3

100
30
40
30

2
2

20
20

1
2
3

10
20
30

6

60
55

Anxiety
2
PTSD
4
Marital status
Never married
2
Married
7
Divorced
1
Key:
GED: General educational diploma
College: Bachelor’s degree
Graduate: Post-Bachelor’s degree
PTSD: post-traumatic stress disorder

20
40
20
70
10

Table 2. Self-reported weekly exercise frequency

Aerobic
Strength
Stretching

Never
n/%
5 / 50
6 /60
5 /50

1-2 x/week
n/%
1 / 10
3 / 30
1 / 10

3-4 x/week
n/%
3 / 30
0
1 / 10

5-6 x/week
n/%
1 / 10
1 / 10
3 / 30

7 x/week
n/%
0
0
0

HRVB Practice
Frequency. Participants were instructed to practice HRVB for 20 minutes during their
weekly study visits and 20 minutes at home twice daily. All practice sessions were recorded by
the emWave2 software. The mean daily practice frequency rate was 0.80, suggesting there were
days when the participants did not practice at all. One participant practiced twice daily during the
first week of the study but not for the prescribed 20 minutes; after that, he only practiced 1-1.3
times per day but for longer periods (25.3 – 39.3 minutes). One participant only practiced during
the first week (mean frequency 0.1), did not practice during week 2, then stopped attending, and
did not return the emWave2, which would have allowed us to collect any additional data. Women
practiced 21.46% more frequently than men (Table 3). All participants had a mental health
diagnosis (Table 1); those with depression practiced 24.4% more frequently than those with
anxiety and 27.16% more frequently than those with PTSD. Not employed Veterans practiced
40.54% more frequently as those who were employed (Table 3).
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Time (minutes). Participants were instructed to practice 20 minutes each session. The
mean practice duration in minutes was 19.36 and ranged from 0 to 58.1 (Table 3), suggesting
that when participants practiced, they did so for the prescribed time. Women practiced 17.57%
longer than men (Table 3). Veterans with a PTSD diagnosis practiced 22.21% longer than those
with a diagnosis of anxiety, and 11.85% longer than those with a diagnosis of depression (Table
3). Those who were not employed practiced only 0.41% longer than those who were employed
(Table 3).
Table 3. HRVB practice frequency and time (minutes)
n=
10
Female
7
Male
3
Depression 6
Anxiety
2
PTSD
5
Employed 3
Not
7
employed

Mean daily
Frequency/(SD)
0.80 (0.51)
0.86 (0.49)
0.61 (0.60)
0.92 (0.52)
0.72 (0.40)
0.70 (0.53)
0.59 (0.36)
0.89 (0.57)

Mean time
(min)/(SD)
19.36 (11.36)
21.12 (10.35)
14.01 (16.63)
19.68 (9.6)
17.73 (5.71)
22.16 (13.83)
19.31 (9.07)
19.39 (12.4)

Time
(min)
Range
0 - 58.1
0 - 58.1
0 - 39.3
0 - 39.3
0 – 22.8
0 – 58.1
0 – 37.2
0 – 58.1

CEQ
We assessed CEQ at the baseline visit. Nine of the participants believed HRVB is a
logical treatment and anticipated it would successfully reduce their pain (n=7). Most expected
50% or greater improvement in their pain (n=8). When asked about how the participants really
feel, half of the participants (n=5) felt that HRVB would reduce their pain, and most (n=7) felt
HRVB would reduce their pain by 50-80%. Prior to trialing the intervention, nine of the
participants did not feel confident enough to recommend this treatment to a friend with similar
symptoms.
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FIQR
FIQR scores were measured at baseline and during weekly study visits thereafter; scores
for each of the three domains and the total FIQR score range from low to high (Table 4). A lower
score represents a better quality of life (51). Functional domain and global impact domain scores
improved post-intervention, suggesting a slight improvement in functional status after HRVB
(Table 4). The mean scores from symptoms of FM were essentially unchanged (63.9 - 64.9),
indicating HRVB did not affect symptoms of FM. The weekly mean total FIQR scores postintervention (128.5) were lower than at baseline (146.6), indicating HRVB improved overall
quality of life.
SFMQ
Pain scores were measured using the SFMQ at baseline and at each weekly visit. Pain
scores did not vary greatly pre- and post-intervention (Table 4). The mean total pain rating index
score was 25.4 at baseline and 25.9 at weekly visits, suggesting there was no improvement or
worsening of pain pre- and post-intervention.
HRC
HRC was measured each time the participant practiced HRVB (Table 4). The mean HRC
recorded at baseline was 1.0, with a range of 0.3 to 1.72. Post-intervention the mean score was
unchanged (1.05); however, we saw a broader range (0.46 to 2.38), suggesting a 29.94% increase
in HRC scores for post-intervention. The highest scores (1.83-2.52) were reached by the two
participants who had the highest rates of HRVB practice frequency (1.1 and 1.9). When we
examined the frequency (n=57) of mean scores, we noted 7 out of 57 practice sessions resulted in
a greater HRC maximum base score of 1.72, indicating most practice sessions (n=50) did not result
in improved HRC week to week (Figure 1).
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Table 4. Outcomes measurements
Baseline
Mean Range
FIQR
Function
64.8 36-90
Global
13.9 5-20
Symptoms
63.9 51-77
Total
143.6 104-181
SFMQ
Sensory
19.1 11-27
Affective
6.6
2-12
Total
25.4 13-39
HRC
1.0
0.3-1.72

SD

Post-Intervention
Mean Range

SD

16.8
5.9
9.7
23.9

51.8
12.4
64.9
128.5

5-90
0-20
16-100
30-210

25.7
6.1
25.2
53.3

6.4
3.3
9.7
0.51

19.9
5.9
25.9
1.05

3-33
0-12
4-45
0.46-2.38

8.5
3.8
11.9
0.59

Figure 1. Scatter plot of HRC total means

Discussion
A purpose of this study was to evaluate the feasibility of Veterans adhering to a
recommended HRVB protocol of twice daily twenty-minute sessions (45) using the emWave2
training device that objectively measures HRV and displays the physiological level of HRC. The
data suggest that twice daily HRVB practice sessions were not feasible for most study
participants. Only one in 10 Veterans, a male, practiced twice daily and then only for one week.
However, overall women practiced more frequently and for longer periods than the men. Three
of the ten participants were employed, which may have impacted their ability to practice twice
daily. Three participants reported frustration with operating the device. Two of them had
difficulty getting a pulse reading from the PPG sensor clipped on their ear, which caused the
device to shut off automatically after a few minutes. One was not able to operate it during the
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last two weeks of the study, and he did not call for assistance or come for his weekly clinic visits.
One participant reported chest wall discomfort if she practiced for more than 10 minutes, so she
avoided trying to practice twice daily. Veterans diagnosed with depression practiced more
frequently than those with PTSD and anxiety. However, Veterans diagnosed with PTSD
practiced for longer periods that those diagnosed with anxiety or depression. This group of
Veterans demonstrated that when they did practice HRVB, they were able to complete a single
20-minute session and some participants tried to make up for the missed sessions with longer
sessions.
The poor adherence to the practice protocol was surprising because most of the
participants reported on the CEQ they believed the treatment was logical and would reduce their
pain by 50-80%. In previous studies, treatment expectancy correlates with treatment outcomes
(46, 47). Additionally, we expected greater adherence given weekly in person sessions with the
PI. We reviewed adherence rates and discussed any barriers to protocol adherence, such as
difficulties with the device and scheduling practice times, at each in person session. The
participants’ poor adherence is more consistent with previous reports that FM patients are
skeptical of treatments (2). We have found no prior HRVB protocol feasibility studies with
which to compare our results. One prior study of HRVB for FM-related chronic pain prescribed
twice daily practice (32); however, the researchers did not report treatment protocol adherence
rates. Other prior HRVB studies for chronic pain did not follow the treatment protocol
recommendations set by Lehrer et al. (45); the studies only provided HRVB training during
clinic visits (31, 43, 54, 55).
The emWave2 software calculates the HRC scores. A lower score indicates a less
coherent HRV, reflecting a dysfunctional ANS, increased pain perception, decreased physical
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function, and poor quality of life (QOL) (19, 21, 56). In our study, the mean HRC scores did not
change substantially from week to week, suggesting there was no improvement in HRV postintervention. This finding is inconsistent with earlier studies, where HRC scores increased with
HRVB (31, 32, 43, 54). Hassett et al. (32) conducted a pilot study of the efficacy of HRVB in
patients with FM and demonstrated a statistically significant (p=0.002) improvement in HRC
after 10 weekly sessions of HRVB training. Soer et al. (43) and Berry et al. (31) conducted pilot
studies of the efficacy of HRVB on chronic pain and also demonstrated a statistically significant
(p < 0.01 and p = 0.01) improvement in HRC after 6 and 4 (respectively) sessions of HRVB
training.
The goal of HRVB is to improve QOL and functional status by decreasing FM-related
symptoms. Data from the SFMQ and the FIQR suggest there was no improvement in pain
symptoms following HRVB. However, despite the persistent pain scores, data from the FIQR
suggests an improvement in the functional status, and an overall improvement in QOL postintervention. Similar findings were reported in the HRVB study for FM patients by Hassett et al.
(32) where they reported a statistically significant (p = 0.0002) improvement in FIQR scores 3
months post intervention, indicating an improvement in QOL. Improved QOL indicators support
treatment that addresses the dysfunctional ANS present in FM (18, 19).
Conclusions
Major limitations of this study were its small size and the lack of a control group. It was
not possible to make inferences about changes in pain, HRV, QOL, or functional status postintervention. Future studies should enroll an adequate number of participants to detect true
changes in outcomes pre-and post-intervention. The participants all self-selected to trial HRVB
and reported a high treatment outcome expectancy of 50-80% improvement in pain. Comparing
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HRVB to sham biofeedback may minimize this self-selection bias. Future studies should also
investigate the protocol adherence correlations between mental health diagnoses.
In summary, it appears a protocol of twice-a-day HRVB practice is not a feasible
treatment option for these Veterans with FM. Yet, the Veterans in this study demonstrated that
once-daily 20-minute practice sessions are acceptable. Findings suggest HRVB was effective in
improving functional status and QOL among our study participants with FM-related symptoms.
Thus, additional larger controlled trials are needed to evaluate this promising self-management
strategy.
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Veterans’ Insights on Heart Rate
Variability Biofeedback to Treat Fibromyalgia-Related Chronic Pain
Abstract
Introduction: The repetitive musculoskeletal stress of wearing heavy gear and exposure to
natural and artificial environmental hazards in the Persian Gulf region has increased the
prevalence of fibromyalgia (FM) among service members. Heart rate variability biofeedback
(HRVB) is a self-management strategy that guides individuals to breathe at a designated
resonance frequency of the cardiovascular system. Resonant breathing may reduce FM-related
symptoms as well as improve physical functioning and quality of life. Although prior research
recommends HRVB for chronic pain, we found no studies testing the feasibility for individuals
with FM regarding protocol adherence or acceptability of the treatment.
Methods: We enrolled 10 Veterans in a HRVB study using a recommended protocol to treat
FM. Veterans were given a HRVB device, emWave2, and instructed to practice at home twice
daily for 20 minutes per session. Following a 7-week intervention period, we conducted an end
of study focus group. We used content analysis to develop themes to determine the feasibility of
engaging in HRVB and adhering to the intervention protocol, as well as insights of Veterans
about the intervention.
Findings: Three common themes emerged: intervention implementation, protocol adherence,
and self-awareness.
Conclusions: Results of this study suggest difficulties operating the emWave2 and scheduling
challenges that interfered with HRVB implementation. However, Veterans reported self-
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awareness of the benefits of HRVB to treat FM-related symptoms. Future studies require a larger
sample size to provide a deeper insight.
Key Words: Fibromyalgia, Veterans, heart rate variability biofeedback, heart rate variability,
focus group
Introduction
Fibromyalgia (FM) is a complex condition characterized by chronic generalized myalgia,
anxiety, depression, sleep disturbance, and fatigue (1). Individual reports of symptoms are
variable with time of day, mood, external stressors, ambient temperature, or the amount of sleep,
leading to dissatisfaction of overall health status (2). Individuals with FM are often frustrated by
the lack of clarity of diagnosis (3) and very little information about treatment options from health
care providers (4).
The Veterans Health Administration (VA) and Department of Defense (DoD)
acknowledge that the repetitive musculoskeletal stress of wearing heavy gear every day during
multiple 6 -12-month deployments during the Gulf War and Afghanistan War increased the
prevalence of FM among service members (5). Additionally, the DoD recognizes that exposure
to natural and artificial environmental hazards in the Persian Gulf region may also contribute to
the symptoms of FM (5). The American College of Rheumatology have set the diagnostic
criteria of FM (6). The diagnosis is based upon the individual’s self-evaluation of pain location
and symptom severity over the past weeks, the symptoms must occur at a similar level for at
least 3 months or lack a disorder that would otherwise explain the pain (6). Because the VA and
DoD have recognized FM as a service-connected condition (5), Veterans have been seeking FMrelated symptom management at a growing rate (7).
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Pathophysiology
In individuals with FM, functional magnetic resonance imaging has demonstrated
disruptions in the regions of the brain that modulate pain inhibition and engage in self-referential
thinking, possibly explaining the symptoms of widespread pain, memory problems, and
cognitive impairment (8, 9). Additionally, the cardiac autonomic nervous system is disrupted,
resulting in an incoherent heart rate variability (HRV) and impacting quality of life (10, 11).
Heart Rate Variability
HRV provides information on the sympathetic and parasympathetic interactions between
cardiac autonomic nervous system (ANS) and ANS, as well as how they function as a whole
(12). HRV is non-invasively analyzed from a plethysmographic (PPG) optical sensor placed at
the fingertip or earlobe (12). HRV coherence, an ordered and harmonic sine-waveform (13),
reflects a healthy functioning ANS associated with minimal pain (14), stress resistance,
emotional adaptability (15), and self-regulation (13). HRV incoherence, an erratic or chaotic
waveform pattern (13), reflects a dysfunctional ANS associated with the chronic pain, decreased
physical functioning, and poor quality of life seen with FM (10, 14, 16).
Treatment
FM treatment is complex, and treatment recommendations vary. However, there is a
consensus in the major guidelines that effective treatment should prioritize non-pharmacological
options that reflect the biopsychosocial model (1, 17). The most recent 2014 VA/DoD Clinical
Practice Guidelines (18) recommend a step treatment for chronic pain that prioritizes multidisciplinary non-pharmacological modalities, which includes strategies like cognitive behavior
therapy, exercise, psychosocial rehabilitation, physical and occupational therapy, acupuncture,
spinal manipulation, complementary and alternative medicine, and biofeedback (1, 19).
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Heart Rate Variability Biofeedback
Heart rate variability biofeedback (HRVB) is a self-management strategy using visual
biofeedback to guide the individual to breathe at a designated resonance frequency of the
cardiovascular system (4-6 breaths per minute) (20). This breathing frequency causes the heart
rate to increase with inhalation and decrease with exhalation, inducing heart rate variability
coherence (HRC), as well as ANS regulation (11, 13, 21-24), which may intensify the interaction
between autonomic and nociceptive pathways (11). By improving HRC and ANS regulation,
HRVB can effectively assist individuals in reducing or preventing FM-related symptoms such as
chronic pain, fatigue, anxiety, and memory problems (25, 26). HRVB also has the potential to
improve emotion regulation, stress resistance, physical functioning (23, 24, 27), and QOL (13,
21, 24) in those with FM.
Optimal resonance breathing differs for each person, so it is difficult for individuals to
achieve and sustain an optimal breathing rate to reach HRC by simply breathing slower than
usual (20, 28). HRVB training must occur gradually to adjust to a such a slow rate (28).
Biofeedback devices, such as the emWave2 (29), use a light display to guide the individual to
breathe at his or her optimal resonant frequency, which will adapt with practice as respiratory
and baroreflex function improve (28). Lehrer et al. (20) recommend 5 clinic visits for HRVB
training with an HRVB-trained health care professional, along with twice-daily 20-minute athome HRVB practice sessions (20, 28). The developers of emWave2 recommend 4-6 training
sessions with a trained health care provider (41), and previous studies assessed the efficacy of
HRVB with 4 to 10 training sessions with a health care provider’s guidance (33, 35, 39).
However, we found no studies assessing the feasibility of individuals adhering to the
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recommended HRVB protocol or the acceptability of the intervention to treat symptoms
associated with FM.
Theoretical Framework
The Principal Investigator (PI) used the theory of symptom self-management (TSSM) to
guide this study. The central tenant of TSSM is that when patients optimize self-directed and
self-managed interventions they experience better cognitive performance outcomes for quality of
life and functional status (26, 30). Additionally, perceived self-efficacy-enhancing interventions
(PSI) like biofeedback can reduce, relieve, or decrease the frequency and duration of pain (25,
26). Lastly, improving patient self-efficacy with cognitive behavioral strategies like HRVB can
shift the patient’s perception of helplessness to confidence regarding the ability to self-improve
(31).
Methods
Design
Aim one of this multi-method study was to explore the feasibility and acceptability of
HRVB as a treatment for Veterans with FM-related chronic pain. Before participant recruitment,
the Institutional Review Board (IRB) at the Medical University of South Carolina and the
Research and Development Review Board (R&D) at the Ralph H. Johnson Veterans Health
Administration (RJVA) in Charleston, South Carolina, approved the study protocol.
Recruitment & Sample
We aimed to recruit 10 participants for this study based upon recommendations for
adequate sample size in a feasibility study (32, 33), as well as constraints to the purchase of
HRVB devices.
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The PI placed IRB and RJVA R&D-approved recruitment flyers in the lobbies and exam
rooms of the primary care and mental health clinics of the RJVA Medical Center. Additionally,
the PI gave flyers to the primary care providers, mental health providers, and nurses in the clinics
and provided them with information about the planned study. The health care staff was not
involved in the study and did not receive a finders’ fees for referrals.
Inclusion criteria were as follows: Veterans of all races, ethnicities, and genders; aged 18
or older; with a documented diagnosis of fibromyalgia. Exclusion criteria were as follows: a
history of a major cardiovascular or pulmonary disease, current use of heart rate regulating
medications; major psychosis; self-reported pregnancy; or prior HRVB experience.
To promote participation and retention, participants received a $5 gift card following
completion of each visit. The PI also reminded participants of the date and time of their next visit
and called them the day before the visit to remind them again.
Intervention
After eligible participants consented, they were enrolled and started the study. Based
upon practice protocols recommended by Lehrer et al. (20) and earlier studies of HRVB to treat
chronic pain (23, 24, 27, 34, 35), the PI conducted 8 once-weekly one-hour individual sessions
and asked each participant to participate in a 60-minute focus group session after all participants
had had access to the HRVB device for 7 weeks.
During the initial study visit, the PI gathered demographic data, asked about exercise
habits, and gave each participant an emWave2 HRVB device, which included the PPG and
charger. The PI provided verbal and written instructions for HRVB use, and a practice plan for
home implementation. Each participant practiced HRVB for 20 minutes with the device during
the initial visit and each subsequent study visit. Additionally, based on the protocol use by
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Lehrer et al. (20), participants were instructed to practice HRVB using the emWave2 at home
twice-daily for 20 minutes. The participants were given a phone number to call if they had any
difficulty with the device or the practice schedule, or if they experienced other urgent concerns.
During each visit the PI coached the participant to breath in a resonant pattern that
increased HRC and changed the coherence level indicator on the emWave2 from red (low
coherence), to blue (medium coherence/improving), to green (high coherence/optimal).
Participants were coached to breathe at the green light level as long as possible during each 20minute practice session. Each visit, the PI downloaded data from the emWave2 and reviewed the
practice frequency, length of practice sessions, and HRC levels with each participant. The PI
discussed any problems with device and tried to resolve any difficulties the participant
encountered. The PI also discussed strategies to adhere to the practice protocol and encouraged
the participants to continue to practice.
Focus Group Conduct
To address aims 2 and 3, the PI conducted a 60-minute post-intervention focus group
session after participants had access to the emWave2 device for 7 weeks. Before the initiation of
the focus group, the PI consulted researchers with experience in focus group mediation and
chronic pain management. The focus group, moderated by the PI, took place at the VA primary
care clinic, where all study visits were also conducted. All study participants (n=10) were invited
to participate; seven participants attended the discussion. Two of the seven participants arrived
20 minutes after the start of the session.
All focus groups participants consented to participation before attending the session. The
focus group started with a short introduction, as well as reminders of participant confidentiality,
such as not sharing what was said outside of the meeting and not using names during the
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meeting. We informed the participants that the meeting was being audio recorded and would be
transcribed verbatim for data analysis. A predetermined set of open-ended questions guided the
meeting; the questions were designed to elicit qualitative information about the participants’
ability to adhere to the HRVB protocol, as well as the acceptability of the intervention as a
treatment for FM-related symptoms. We also asked open-ended questions about changes in pain
severity and FM-related symptoms to explore the initial signal of efficacy of HRVB. We
explored the hypothesis that self-directed, self-managed PSI such as HRVB would improve
cognitive performance outcomes for QOL and functional status (26, 30).
Data Analysis
We assessed the feasibility of recruitment of Veterans with FM by tabulating the
responses to the study advertisement and study enrollment figures. Additionally, we evaluated
the frequency of respondents which met exclusion criteria. We assessed individual attendance
rates as well as the number of participants which attended the focus group session to evaluate
retention.
The author organized the data for content analysis using manifest and latent analysis (36)
for the identification of themes regarding feasibility and acceptability. To increase data validity,
a highly experienced qualitative researcher performed an independent analysis and discussed the
results with the PI to obtain a consensus (36). We labeled the data with codes and categorized
them into themes (36, 37).
Feasibility was defined as participants’ ability to operate the emWave2 as well as
implement follow the prescribed intervention protocol. With regard to the theoretical framework,
when individuals can implement the practice of HRVB, they are able to attain the established
goals of following the protocol and the desired outcomes of decreasing the symptoms of FM
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(26). We defined acceptability as the participants’ self-reported willingness to follow the practice
protocol and self-reported physiological and psychological responses to the intervention.
Individuals who interpret their own strengths and weaknesses to achieve a goal are more
successful with PSE enhancing interventions like HRVB (26).
Results
Recruitment/Retention
After three weeks of advertising, 13 individuals from the VA primary care and mental
health clinics expressed interest. One respondent was not a Veteran; he was given the flyer by a
Veteran who saw it in the lobby. One respondent could not commit to the weekly visits because
of her full-time work schedule, and another respondent did not meet the eligibility requirements
because he was being treated with a cardiac regulating medication. The remaining respondents,
n=10, met eligibility requirements, provided informed consent, and were enrolled in the study.
Eight of the ten participants attended 75-100% of the study visits (Table 1), and seven of
ten attended the end of study focus group session. Veteran 6 (Table 1) did not return to the clinic
after week 3. The PI called Veteran 6 each week to remind him of his appointment, and each
time he stated he would come to the following visit. The PI asked Veteran 6 why he missed the
previous visit, and he reported he became distracted and forgot, had unexpected family
obligations, and the last two visits he reported either he, his wife, or his children were ill with
upper respiratory symptoms. Veteran 6 lives 1.5 hours away from the clinic, which may have
also been a contributing factor. Veteran 5 (Table 1) attended the first two visits and the 7th visit.
The PI called her the day before each scheduled visit to remind her; however, she never
answered the phone, and the PI was not able to leave a message for her. During her visits, the PI
asked about barriers to participating and her response was, “I was not feeling well.” The PI
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continued to encourage her to practice her resonant breathing between visits. The participant
dropped off her device at the front desk of the clinic at the end of the study, and she did not
attend visit 8 or the focus group. Data from her device indicated she practiced 27 of the 49 days
(55.1%) of the study.
Table 1. Weekly attendance rate
Weeks
1 2 3 4
Veteran
1
A
A A
2
A A A A
3
A A A A
4
A
A
5
A A
6
A
A
7
A
A A
8
A
A A
9
A A A A
10
A A A
Key: A = attendance
FG = focus group

5

6

7

8

Freq %

A A A A 7
A A A A 8
A A
6
A A A A 6
A
3
2
A A 5
A A A A 7
A A A
7
A A A A 7

87.5
100
75
75
37.5
25
62.5
87.5
87.5
87.5

FG
A
A
A
A
A
A
A

Participant Characteristics
We enrolled 7 women between the age of 33 and 68 years (mean=52) and 3 men between
the ages of 33 and 54 years (mean =47). The participants were white (n=5) or African American
(n=4). One participant self-selected Hispanic ethnicity yet declined to self-select race. All had at
least some higher education (Table 2). Only 3 participants were employed. All participants had a
mental health diagnosis of depression (n=6), anxiety (n=2), and/or post-traumatic stress disorder
(PTSD) (n=4). Most (70%) were married. Four of the seven women reported exercising
aerobically, with strength training and/or stretching (Table 3). One of the three men reported
aerobic exercising and stretching (Table 3).
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Table 2. Participant demographics and baseline history

Gender
Female
Male
Race/ethnicity
White
African American
Hispanic
Education
HS/GED
Partial college
College degree
Graduate level
Employment
Unemployed
Fulltime
Medically disabled
Working
Unable to work
Retired
Mental health
Depression
Anxiety
PTSD
Marital status
Never married
Married
Divorced

Frequency Percent
7
3

70
30

5
4
1

50
40
10

10
3
4
3

100
30
40
30

2
2

20
20

1
2
3

10
20
30

6
2
4

60
20
40

2
7
1

20
70
10
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Table 3. Self-reported weekly exercise frequency

Aerobic
Never
1-2x/week
3-4x/week
5-6x/week
7x/week
Strength
Never
1-2x/week
3-4x/week
5-6x/week
7x/week
Stretching
Never
1-2x/week
3-4x/week
5-6x/week
7x/week

Overall
(n=10)

Female
(n=7)

Male
(n=3)

50% (5/10)
10% (1/10)
30% (3/10)
10% (1/10)
0

42.8% (3/7)
14.3% (1/7)
28.6% (2/7)
14.3% (1/7)
0

66.7% (2/3)
0
33.3% (1/3)
0
0

60% (6/10)
30% (3/10)
0
10% (1/10)
0

42.8% (3/7)
42.8% (3/7)
0
14.3% (1/7)
0

100% (3/3)
0
0
0
0

50% (5/10)
10% (1/10)
10% (1/10)
30% (3/10)
0

42.8% (3/7)
0
14.3% (1/7)
42.8% (3/7)
0

66.7% (2/3)
33.3% (1/3)
0
0
0

Feasibility of Prescribed HRVB Protocol
To address the feasibility of the HRVB protocol, the facilitator asked participants if they
had difficulty following the home practice schedule of 20 minutes twice daily, and if so, what the
difficulties were. The resulting data were coded as implementation and adherence.
Implementation
A common barrier to implementation of the protocol was difficulty finding time to
practice. Three participants work full time jobs; one participant cares for her husband who is
receiving chemotherapy and she drives him to his appointments. Another participant is a
caregiver to her disabled husband and actively helps care for her young grandchildren. These
barriers were also identified and addressed during the weekly individual visits. The PI addressed
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these barriers and helped the participant identify strategies to overcome these barriers. Some
strategies were setting aside 20 minutes before the children got up in the morning, or before they
came home from school, using lunch break to sit in a quiet area of the building or in the car to
practice. In the case of the participant’s spouse was receiving chemotherapy, the PI suggested
practicing in a quiet place while she was waiting for him to complete his treatment. Three
participants were strictly adhering to a stressful schedule and preferred to practice when it was
convenient. The following are salient responses:
Veteran 7 stated, “I stressed out over it, because my work schedule's weird, so
trying to get it on a consistent schedule was difficult and then, I would get frustrated
with myself, because I didn't do it like I was supposed to.”
Veteran 1 reported, “I found it a lot easier for me to just use it anytime it was
convenient for me, as I was driving, I was going for appointment, I was waiting, or
whatever the case may be, I just made it work with my schedule, because if I tried
to just do it twice a day at a given time, it just didn't really work for me.”
Veteran 3 summed it up by stating, “We are all too busy, everybody’s always too
busy.”
Another identified barrier to protocol implementation was difficulty operating the device.
The most common problem reported was with the PPG. Participants had difficulty getting a
pulse when they clipped the PPG to their earlobe.
Veteran 3 reported, “It wouldn't work on my finger. Periodically, it worked on different
places on my ears.”
A key feature of the emWave2 is that the device shuts off automatically if there is no pulse
reading. Some of the participants reported frustration about the device shutting off during the
individual study sessions. These frustrations were reiterated during the focus group session.
Veteran 4 stated, “It would kill my ears, I had to use my finger, and it wouldn’t read
the pulse all of the time.”
Veteran 6 reported, “Mine would completely stop working. I thought it had died, it
turns off.”
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The PI addressed these difficulties during the study sessions. The researcher assisted the affected
participants by trying different areas of the ear, and by attaching the PPG to the fingertips.
Two participants reported it would have been helpful to have a resource video to refer to
for technical difficulties. One participant was able to find a freely available video online for the
emWave2 and was able to alleviate the problem of finding a pulse with the PPG.
We identified implementation facilitators during the focus group session and during
individual visits with the PI. Veteran 7 and Veteran 2 implemented the practice protocol because
they believe biofeedback is an acceptable treatment alternative to medications and other more
invasive treatment options they have tried in the past. Veteran 9 reported he had heard of the
psychological and physiological benefits of HRVB in the media and was anxious to start the
prescribed protocol.
Veteran 5 reported she was able to implement the intervention if she did not try to follow
a schedule. She stated it was easier for her to practice at her convenience, like when she was
driving on her way to appointment or waiting in an office or waiting room. The PI advised the
Veteran not to practice HRVB while driving because the practice of HRVB may detract her from
driving safely. She verbalized understanding and assured the PI she would refrain from such
behavior in the future.
Adherence
Four of the participants reported they tried to make up for missed practice sessions by
practicing for longer than the prescribed 20-minute sessions or practicing extra sessions when
they had time.
Veteran 10 reported, “I missed some days, too, but when I do remember, I always
do like three times because I actually need to bring my heart rate down back to
where I need it to.”
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Veteran 3 stated, “If once a day then for an hour, twice a day most times.”
One participant reported he followed the practice protocol because he had watched a
video about the physiological changes that occurs when one engages with HRVB. Some
participants reported the visual feedback system of the emWave2, the HRC indicator light
changing from red (low HRC) to blue (moderate HRC) and to green (optimal HRC) (38), was a
beneficial factor in their protocol adherence.
Veteran 1 reported, “I thought the lights were helpful, when you were in bed
breathing you can see a difference. You didn’t want it to stay red. It would gradually
go to blue and then green. If you stayed in the green you would hear pop pop pop
and I know I am doing it right.”
The study team identified some barriers to adherence. Participants reported
inconveniences of carrying the emWave2 with them. They reported they may have been more
compliant with the protocol if they could have practiced on their cell phones, which they carry
everywhere. Veteran 10 reported, “I don’t see it, I don’t remember.” One participant was
bothered by the beeping sounds emitted from the device and curtailed the practice time to avoid
the sounds. The “beeping” problem was resolved during the next clinic visit after receiving
guidance about how to control the audio features.
Lastly, one Veteran reported “chest pain” if she practiced for the prescribed 20 minutes,
resulting in less time spent during each practice session as well as fewer practice sessions during
the week. Her reported chest pain was evaluated by the PI during the individual clinic visit and
determined to be chest wall pain and not cardiac pain. Participants were instructed to seek
emergency medical care for any urgent cardiac-related symptoms. Her symptoms gradually
improved from week to week, and by the end of the 8-week study, she was able to practice for
20-minutes with minimal chest wall discomfort.
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Acceptability of the intervention
The facilitator asked participants if the intervention helped with pain or other FM-related
symptoms like sleep, depression, anxiety, or memory. One of the foundations of PSE-enhancing
interventions is individual interpretation of inferences from physiological and psychological
responses that indicate personal strengths and vulnerabilities to reach goals of the intervention
(26). The discussion data were coded as self-efficacy of HRVB. Results related to self-efficacy
of pain symptoms were mixed: 2 of 7 reported some relief in pain, 2 of 7 reported they were
unsure if they experienced pain relief, and 1 of 7 reported no pain relief.
Veteran 10 reported, “So, I had to use it to calm me down too, because I realized
with it, it also by calming me down and getting my breathing under control, it would
help with the pain too, because last time, I'd been in pain all the time, so it kind of
helped.”
Veteran 4 stated, “It's hard to tell because I still get injections in my back. I get
infusions once a month because I've got multiple things going on, so it's really hard
to tell. It was relaxing.”
Veteran 4 added, “Yeah, and so yeah it helped with the muscle spasms and all that,
but as far as the pain, I live with it.”
Participants reported changes in other FM-related symptoms, such as breathing,
relaxation, cognition, and sleep. Participants recognized that when they engaged in the resonant
breathing, they experienced relaxation and decreased anxiety, which directly impacted pain
tolerance.
Veteran 1 shared, “The other thing I found was you hear a lot about how your body
naturally heals itself, but with this machine, you also realize how the body impacts
you as a person and what you do to help your body heal itself can make a difference,
because when I used the machine, I notice a lot of things about my own body, how
my body reacts to how I breathe, how I feel, after the machine and even before the
machine, because it made a difference in how I was feeling."
Veteran 1 added, “It made a difference in my pain level too with my breathing, and
I've always practiced breathing, but I've never practiced it on a machine where I
could actually just see how it affected me, calmness, anxiety, different things that
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were happening at different times and that's when I realized too, use the machine at
night and then, in the morning. Sometimes, at night, during the day, depending on
what I'm doing and when I'm having real, I just want to slap somebody ... and
noticed a difference in how I was feeling and what I was doing when I stopped and
used the machine.”
Veteran 9 stated, “Especially when I did it in the evening, it also helped the sleeping
tremendously. Because you were getting into a relaxed state, which does help you
sleep.”
They were aware that mental distraction increased a sense of calmness and self-corrected
when the indicator lights turned red.
Veteran 8 reported, “So, just in terms of the thought distraction helps overall
calmness feeling and then, but when it did go red, it made me more aware of what
I was feeling at the time physically and mentally, and it was kind of an, ‘Oh,’ it
helped me make those connections.”
We also evaluated intervention acceptability by asking the participants if they would
recommend HRVB to other Veterans with FM. The responses were a unanimous yes. They felt
HRVB was a good alternative to medication and an option when all else has failed.
Veteran 9 reported, “I think there's a lot to be said with biofeedback, especially
when you've tried everything else.”
Veteran 3 stated, “It's a good alternative to medications and other extensive medical
practices.”
Discussion
HRVB is a promising self-treatment option to improve the FM-related symptoms like
pain, mental fog, anxiety, and sleep disturbance, as well as functional status and QOL (13, 21,
24). Lehrer et al. (20) determined individuals cannot simply achieve HRC by slowing their
breathing rate and thus developed an HRVB training protocol to optimize resonant breathing to
reach optimal HRC. However, we failed to find any research to support the feasibility or
acceptability of the prescribed protocol for individuals with FM.
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Core elements of self-management skills include decision making, resource utilization,
and problem solving (26). When participants were instructed to practice HRVB twice daily for
20 minutes, they had to choose to make time to practice and to avail themselves of the resources
provided, e.g., by calling the PI for any difficulties and/or discussing barriers to the practice
protocol, and with the PI’s guidance, problem solving any difficulties with the device.
Individual perceived self-efficacy (PSE) beliefs are not only developed through
performing an activity (26). PSE is also developed by observing others successfully
understanding an activity, and by social or verbal persuasion that one can be successful (26),
received either from peers or healthcare providers. Our study participants did not have an
opportunity to observe others practice HRVB, and they only received encouragement from the PI
during the in-person session. In future trials, to help improve participant self-efficacy, we
recommend providing participants with a calendar, negotiating an acceptable schedule during the
initial study visit, and reviewing the schedule for adjustments as the individual encounters
implementation obstacles. We also suggest conducting multiple focus groups during the study to
provide opportunities for participants to discuss implementation barriers with other participants
as well as observe helpful techniques.
Additional core elements of self-management skills include decision making, resource
utilization, and problem solving (26). When the Veterans encountered difficulties with the PPG,
they became frustrated and practiced less frequently. Participants were given a phone number to
contact the PI and instructed to call at any time between the hours of 0700 and 2100. No
participants called the PI for assistance. In future studies we may include an instructional video
for individual reference. Future study protocols also may include instructions on how to access
online help from the manufacturer of the HRVB device. HeartMath®, the makers of the
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emWave2, have an online forum for technological problems (39). Some Veterans reported the
device itself was inconvenient because it was another object to carry with them. HeartMath® has
software for mobile phones that operates similarly to the emWave2 device (40). Future trials may
consider utilizing HRVB software that can be downloaded onto a mobile phone.
FM-related symptoms can vary from day to day, depending upon elements such as sleep,
stress, or ambient temperature, potentially leading to frustration and feelings of lack of control
over symptom self-management (2); those factors may contribute to skepticism of treatment
recommendations (4). Gaining control with activities like HRVB may maximize symptom
management (26). Although Veterans did not report complete pain relief, there was some
improvement in pain and there was a consensus of overall improvement in other FM-related
symptoms such as sleep, cognition, and relaxation. Ease of relaxed breathing, improvements in
sleep, increased calmness, and improved cognition were all interrelated and have been
demonstrated in other studies to improve QOL in individuals with FM (1, 6, 41). In their HRVB
study for FM, Hassett et al. (24) reported similar results to ours: an improvement in functional
status, relief of FM-related symptoms, and improvement in QOL.
In our study there was an isolated case of chest wall pain associated with the resonant
breathing of HRVB. We did not discover any complaints of chest wall pain in earlier studies of
HRVB to treat FM-related pain or chronic musculoskeletal pain (23, 24, 27, 35, 42, 43).
However, this should be addressed and reported if discovered in future trials. Researchers should
also stress the importance safely practicing HRVB, like while driving or conducting activities
that requires their full attention.
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Conclusion
HRVB is a promising treatment option for FM-related symptoms. Limitations of this
study include the small sample size. Additionally, the PI led a single focus group session. The
participants were asked to recall events and experiences over an eight-week period.
Our findings indicate that there were difficulties operating the device and scheduling
challenges that interfered with implementation of the intervention. Future trials may be able to
prevent some of the equipment difficulties with clearer instructions and participant access to the
developer’s website. Although our qualitative analysis suggests HRVB is an acceptable
treatment for Veterans with FM, more detailed interviews from a larger sample are needed.
Adding individual interviews at several points throughout the study may provide deeper insight
into the acceptability of this novel treatment option.
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Summary
As the incidence rates of fibromyalgia (FM) rise in U.S. Veterans, (1) health care
providers are challenged to find safe, effective, and acceptable treatment options. FMrelated symptoms are complex (2-4), and treatment must be multi-focal (5). Heart rate
variability biofeedback (HRVB) is a self-management strategy (6) that has the potential
to improve emotion regulation, stress resistance (7-9), and quality of life (9, 10) for
individuals with FM. Repeated sessions of HRVB can optimize stress resistance,
decrease pain, and increase overall well-being (6). The overarching question of whether
HRVB is a feasible and acceptable treatment for Veterans with FM-related chronic pain
is covered in three manuscripts. The first manuscript is an integrative literature review
examining the relationship between HRVB and FM-related chronic pain. The second and
third manuscripts report the quantitative and qualitative findings of the feasibility and
acceptability study we conducted of HRVB to treat FM-related chronic pain.
In the first manuscript, we examined the relationship between HRVB and FMrelated pain through the lens of the TSSM. We reviewed five studies that reported the
results of HRVB as a treatment for chronic musculoskeletal pain (7, 8, 11-13) and one
study investigating HRVB to treat FM-related chronic pain (9). All six authors reported
an overall improvement in chronic pain (7-9, 11-13); however, only Hassett et al. (9),
Hallman et al. (8) and Soer et al. (11) reported changes in functional status and quality of
life. Hassett et al. (9) reported improved functional status and quality of life after HRVB
from results of the Fibromyalgia Impact Questionnaire (FIQ). Soer et al. (11) and
Hallman et al. (8) reported improvements in vitality as well as functional and social status
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after HRVB from the Short Form Health Survey (SF-36). However, these were pilot
studies that were not designed to test a hypothesis (14). HRVB practice protocols
reported in manuscript 1 were inconsistent, so it was difficult to determine if the
researchers implemented Lehrer’s (15) protocols.
Additionally, we were not able to determine if outcomes of functional status and
quality of life were related to the intervention. We did not identify any studies that
addressed individual adherence to the practice protocols of HRVB as an intervention to
treat FM-related chronic pain. Finally, we did not locate any qualitative studies that
examined participant acceptability of HRVB as a treatment for FM-related pain.
Manuscript two reported the feasibility and adherence to a recommended HRVB
protocol. We enrolled 10 Veterans to evaluate feasibility and adherence to a twice a day,
twenty-minute HRVB practice protocol on the emWave2 device for eight weeks. The
Veterans in our study did not adhere to the recommended twice-daily practice protocol.
Veterans cited scheduling difficulties related to jobs, family care obligations, and
otherwise busy schedules as barriers to the practice schedule. However, the Veterans
practiced for the recommended 20 minutes whenever they made the time for practice. We
examined earlier studies but did not locate any studies that allowed participants to take
the HRVB device for home practice.
In manuscript two we also reported data from the FIQ and noted that overall
participants did not reports any significant change in FM-related symptoms like pain,
fatigue, depression or memory problems. However, consistent with findings reported by
Hassett et al. (9) the participants did report a slight improvement in functional status, like

93

being able to complete some household chores, walking for 20 minutes or climbing one
flight of stairs, and an overall improvement in the quality of life post-intervention.
As stated earlier, we did not identify any qualitative studies of HRVB to treat FMrelated symptoms. To address this gap in the literature, we conducted a focus group postintervention seeking Veterans’ insights into the twice-daily 20-minute HRVB protocol
and reported the results in manuscript 3. While we were able to determine the Veterans
did not practice twice daily as instructed, it was valuable to discover why they did not
practice. The Veterans reported family obligations, work schedules, and difficulties
adhering to a new habit as barriers to practice. The participants also reported some
difficulties managing the settings on the HRVB device that interfered with the practice
schedule. Although not reflected in the answers reported on the FIQ, during the focus
group sessions, the Veterans reported the realization of a connection between HRVB and
improved FM-related symptoms like sleep and anxiety. Additionally, the participants in
the focus group reported decreased pain levels; however, this was not reflected on the
quantitative pain scales they completed at each individual visit. The Veterans also viewed
the visual feedback of the emWave2 as helpful in maintaining the positive effects of
HRVB. This insight will be helpful when we develop future HRVB study protocols.
There were several limitations to this dissertation. This study was small (n=10)
and did not have a control group. Confounding variables such as other pain treatment
modalities may have influenced the outcomes of this study. Although all participants met
inclusion criteria, 50% (n=5) of the study participants were known to the PI through prior
care in the Veterans Administration (VA) pain clinic; thus, there was a risk of selection
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bias. A larger randomized controlled trial of participants recruited from multiple clinics
may minimize these limitations.
This PI had limited experience in conducting a focus group. After review of the
focus group transcript and discussions with a seasoned qualitative researcher, we
identified several limitations. Although the PI kept to the pre-determined focus group
script, she did not recognize several opportunities to obtain deeper insight into the
Veterans’ experiences with the intervention. If the PI had ventured from the script and
asked for further clarifications to comments by the participants, she may have gained
richer valuable data about the barriers to the practice protocol as well as insights about
participant self-efficacy of the benefits of HRVB. Additionally, the PI only conducted
one focus group at the end of the study. When the PI was developing the study protocol,
she believed one post-intervention session would be enough to gain insight into the
Veterans’ experiences with HRVB. However, the participants were asked to recall
insights into interventions over eight weeks, and the PI now recognizes that participant
recall may have been improved with additional meetings at various points throughout the
study.
None of the HRVB studies we identified in our integrative literature review
(manuscript 1) applied a theoretical or conceptual framework. Future research about
biofeedback to treat FM-related symptoms should use a theoretical framework that
addresses self-management and self-efficacy to increase treatment adherence and
optimize performance outcomes such as functional status and quality of life. This
dissertation study was guided by the central tenant of TSSM, that implementation of selfmanagement interventions improves performance outcomes like quality of life and
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functional status. An important construct of TSSM to consider is that activities such as
social and verbal persuasions from peers and observing others perform the activity
successfully can assist individuals to identify their strengths and vulnerabilities to achieve
their goal (16). Peer mentorship or group visits may be useful in future studies.
I want to continue my investigation of HRVB as a treatment option for Veterans
with FM. The VA is committed to developing and integrating non-pharmacological
modalities into individual pain care plans. My goal is to conduct a pilot study of HRVB
for the treatment of chronic pain in Veterans with FM. I will update my integrative
literature review with any new studies conducted to treat FM with HRVB. I will review
the findings of this study to develop a study protocol that may minimize some of the
limitations identified. HRVB is being used within the VA to treat post-traumatic stress
disorder, so I will communicate with the champions of HRVB, and discuss strategies for
obtaining the HRVB devices, planning a study protocol, and recruitment strategies. I plan
to apply for the VA Nursing Research Initiative grant and work closely with pain team
members and seasoned researchers.
Implications
The results of this dissertation have several implications for health care provider
education, clinical practice, and future research for FM-related chronic pain treatment.
This dissertation introduces medical providers to an alternative to pharmacological
treatment for FM-related chronic pain that is safe and accepted by individuals with FM.
The information provided in the integrative literature review (manuscript 1) will inform
health care providers of the gap in the literature concerning the feasibility of following
the recommended HRVB protocol and lack of studies of HRVB as a treatment option for
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FM-related pain. The quantitative study (manuscript 2) informs health care practitioners
who plan to implement HRVB into their pain treatment plan that a twice-daily 20-minute
practice protocol is not feasible for individuals with FM and may require adjustment.
Although this quantitative study (manuscript 2) was not designed to provide inferential
statistics, we did recognize a suggestion of individual improvement in functional status
and quality of life post-intervention. Results of the qualitative study (manuscript 3) will
inform practitioners that individuals reported difficulties following the treatment protocol
because of scheduling and family obligations. Health care providers can use this
information to anticipate barriers to the prescribed protocol and help patients identify predetermined scheduling conflicts and develop an individual schedule that is easy to
maintain. Health care providers will learn that although the participants were unable to
follow the recommended protocol, they acknowledged the positive physiological and
psychological effects.
The implementation of HRVB for FM-related chronic pain follows current
treatment guidelines that prioritize nonpharmacological treatments based on the
biopsychosocial model (5, 17). The emWave2 device is affordable and readily available
on the general market (18). With this novel approach, health care providers may
empower individuals to self-manage their FM-related chronic pain. Additionally, FM
patients are often skeptical of pharmacological treatments for their symptoms (19) and
are more receptive to holistic providers (20) that offer treatments like HRVB.
Future research
The integrative literature review (manuscript 1) demonstrates the need for
additional research investigating the use of HRVB as an acceptable treatment option to
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manage the chronic pain associated with FM. Additionally, we were unable to locate
prior studies that address the feasibility of individuals with FM to adhere to the
recommended HRVB protocol. Although our quantitative study (manuscript 2) results
suggested an improvement in functional status and quality of life in individuals with FM,
randomized controlled trials that are adequately powered to determine HRVB outcomes
are needed. The integrative literature review (manuscript 1) also supports the need for
qualitative studies that will investigate individual insight into this novel approach, so that
health care providers can provide an acceptable and safe treatment alternative.
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status of this project or your role in the project changes, please notify the VA
Research Office immediately in writing. Should you have any questions, please
contact Rudell Ryant, R&D Program Manager, at 789-6711.
2. You, the Principal Investigator, are responsible for notifying your Service Chief,
Impacted Services/Clinics and Pharmacy Service (if applicable) of IRB and R&D
approval. You, the Principal Investigator, are also responsible for notifying your
Service Chief, Impacted Services/Clinics and Pharmacy Service (if applicable)
when a study has been terminated.
3. Please take the time to read the attached VHA Handbook 1200.19, dated July 10,
2014. It describes VA policy regarding acknowledgment of Department of
Veterans Affairs affiliation and research support in presentations and publications.
In publications, the proper terminology is: This work is supported by the Office of
Research and Development, Medical Research Service, Department of Veterans
Affairs.
4. All research staff that are not VA employees must be registered as WOC
employees and their credentials confirmed.
R. Amanda C. LaRue, Ph.D.
Attachment:

VHA Handbook 1200.19
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Appendix D
Recruitment flyer for study reported in manuscript 2 & 3

Who is eligible?
Veterans over 18
Diagnosed with
Fibromyalgia
────
What is involved?
Interviews and
questionnaires
Non-medication
pain management
technique

FIBROMYALGIA
PAIN?
Research Study

Researchers at the R. Johnson VA and Medical University of
South Carolina are looking for volunteers with Fibromyalgia to
participate in a research study to investigate the effect of a nondrug treatment on pain and quality of life.

Duration
12 weeks
────
Compensation is
available

CO-INVESTIGATOR
Marcelaine Haire
843-367-9220
Marcelaine.haire@va.gov
R. Johnson Department of
Veterans Affairs
Goose Creek Clinic
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Appendix E
Focus group questions for study reported in manuscript 3
Focus Group Questions
Set 1 Questions
1. How often did you use the device?
2. Did you look forward to using it?
3. Do you think if helped your pain?
4. Did it help anything else besides pain?
5. Was there a downside to using it?
6. Do you think there could be a better way of teaching this to people?
Set 2 Questions
7. Did you have any technical difficulties? If so, what were they? How did they get
resolved? Did the problem(s) change your practice schedule?
8. Were you frustrated with the device?
9. Did you have any difficulty following the home practice schedule? If so, what were
they? What kind of changes did you make to the home practice schedule?
10. If you could talk to other Veterans with FM, what would you tell him/her about your
experience with HRVB?
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Appendix F
Demographics questionnaire for study reported in manuscripts 2 & 3
GENERAL BACKGROUND INFORMATION
1. Today’s date: __/__/___ (month/day/year)
2. Age: ____
3. Gender: (check one)
1. __Female
2. __ Male

4. Race (check all that apply)
1. __White
2. __ Black or African American
3. __ American Indian or Alaskan Native
4. __ Asian
5. __ Native Hawaiian or Other Pacific Islander

5. Ethnicity

1. __ Hispanic or Latino

6. Highest level of school completed (check one)
1. __ High School graduate (includes GED)
2. __ Partial college or vocational training
3. __ College or university graduate
4. __ Graduate professional training

7. Employment status

1. __ Unemployed
2. __ Seeking employment
3. __ Medically disabled, unable to work
4. __ Medically disabled, working
5. __ Part-time employed
6. __ Full-time employed
4. __ Retired

8. Mental health history (check all that apply)

1. __ Depression
2. __ Anxiety disorder
3. __ PTSD
4. __ Panic disorder
5. __ Other, please specify (_________________________________)

9. Marital status (check all that apply)
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1. __ Never married
2. __ Married
3. __ Separated
4. __ Divorced
5. __ Widowed

10. How many days per week do you walk, use elliptical machine, bike, swim, dance
or perform other movement activities for at least 30 minutes? (check one)
1. __ Never
2. __ 1-2 times a week
3. __ 3-4 times a week
4. __ 5-6 times a week
5. __ 7 times a week

11. How many days per week do you use any weights to strengthen your muscles for
at least 15 minutes? (check one)
1. __ Never
2. __ 1-2 times a week
3. __ 3-4 times a week
4. __ 5-6 times a week
5. __ 7 times a week

12. How many days per week do you stretch your muscles for at least 15 minutes?
(check one)
1. __ Never
2. __ 1-2 times a week
3. __ 3-4 times a week
4. __ 5-6 times a week
5. __ 7 times a week
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Appendix G
Credibility/Expectancy questionnaire for study reported in manuscript 2
Credibility/Expectancy Questionnaire
We would like you to indicate below how much you believe, right now, that the treatment
you are receiving will help reduce your pain. Belief usually has two aspects to it: 1) what
one thinks will happy and 2) what one feels will happen. Sometimes these are similar;
sometimes they are different. Please answer the questions below. In the first set, answer
in terms of what you think. In the second set answer in terms of what you really and truly
feel.
Set I
1. At this point, how logical does the biofeedback treatment offered to you seem?
1
2
3
4
5
6
7
8
9
not at all logical

somewhat logical

very logical

2. At this point, how successfully do you think this biofeedback treatment will be in
reducing your pain?
1
2
3
4
5
6
7
8
9
not at all useful

somewhat useful

very useful

3. How confident would you be in recommending this biofeedback treatment to a friend
who experiences similar problems?
1
2
3
4
5
6
7
8
9
not at all confident

somewhat confident

very confident

4. By the end of the biofeedback treatment period, how much improvement in your pain
do you think will occur?
0%
10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Set II
For this set, close your eyes for a few moments, and try to identify what you really feel
about the treatment and its likely success. Then answer the following questions.
1. At this point, how much do you really feel that the biofeedback treatment will help you
to reduce your pain?
1
2
3
4
5
6
7
8
9
not at all

somewhat

very much

2. By the end of the biofeedback treatment period, how much improvement in your pain
do you really feel will occur?
0%
10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
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Appendix H
Fibromyalgia impact questionnaire for study reported in manuscript 2
REVISED FIBROMYALGIA IMPACT QUESTIONNAIRE (FIQR)
Unique Identifier:
Age:
Duration of FM symptoms (years) :

Time since FM was first diagnosed (years):

Directions: For each of the following 9 questions check the box that best indicates how much
your fibromyalgia made it difficult to perform each of the following activities during the past 7
days. If you did not perform a particular activity in the last 7 days, rate the difficulty for the last
time you performed the activity. If you can’t perform an activity, check the last box.

Brush or comb your
hair
Walk continuously
for 20 minutes
Prepare a
homemade meal
Vacuum, scrub or
sweep floors

Lift and carry a bag
full of groceries
Climb one flight of
stairs
Change bed sheets
Sit in a chair for 45
minutes
Go shopping for
groceries

No difficulty
difficult
No difficulty
difficult
No difficulty
difficult
No difficulty
difficult
No difficulty
difficult
No difficulty
difficult
No difficulty
difficult
No difficulty
difficult
No difficulty
difficult

□□□□□□□□□□□

Very

□□□□□□□□□□□

Very

□□□□□□□□□□□

Very

□□□□□□□□□□□

Very

□□□□□□□□□□□

Very

□□□□□□□□□□□

Very

□□□□□□□□□□□

Very

□□□□□□□□□□□

Very

□□□□□□□□□□□

Very

Sub-total (for internal use only)

Directions: For each of the following 2 questions, check the box that best describes the
overall impact of your fibromyalgia over the last 7 days:
Fibromyalgia prevented me from
Never
accomplishing goals for the
Always
week

□□□□□□□□□□□

I was completely overwhelmed
by my fibromyalgia symptoms

Never
Always

□□□□□□□□□□□
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Sub-total (for internal use only)
FIQR © Robert M Bennett & Ronald Friend, 2009. All Rights Reserved.
FIQR – USA/English – Original version
FIQR_AU1.0_eng-USori

Directions: For each of the following 10 questions, select the box that best indicates your
intensity of these common fibromyalgia symptoms over the past 7 days
Please rate
your level
of pain

Please rate
your level
of energy
Please rate
your level
of stiffness
Please rate
the quality
of your
sleep

No pain
pain
Lots of energy

No stiffness
stiffness

No depression
depressed

Please rate
your level
of memory
problems

Good memory
memory

Please rate
your level
of anxiety

Please rate
your level
of balance
problems
Please rate
your level
of
sensitivity

Unbearable

□□□□□□□□□□□

No energy

□□□□□□□□□□□

Awoke well rested
Awoke very tired

Please rate
your level
of
depression

Please rate
your level
of
tenderness
to touch

□□□□□□□□□□□

Severe

□□□□□□□□□□□

□□□□□□□□□□□

Very

□□□□□□□□□□□

Very poor

Not anxious

□□□□□□□□□□□

Very anxious

No tenderness

□□□□□□□□□□□

Very tender

□□□□□□□□□□□

Severe

No imbalance
imbalance
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to loud
noises,
bright
lights,
odors and
cold

No sensitivity

□□□□□□□□□□□

sensitivity

Sub-total (for internal use only)

FIQR TOTAL (for internal use only)
FIQR © Robert M Bennett & Ronald Friend, 2009. All Rights Reserved.
FIQR – USA/English – Original version
FIQR_AU1.0_eng-USori
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Extreme

Appendix I
Short-form McGill pain questionnaire for study reported in manuscript 2
I.
Short-Form McGill Pain
Questionnaire
A. PLEASE DESCRIBE YOUR PAIN DURING THE LAST WEEK. (Check off one box per line.)
None

Mild

Moderate

Severe

1.

Throbbing

0



1



2



3



2.

Shooting

0



1



2



3



3.

Stabbing

0



1



2



3



4.

Sharp

0



1



2



3



5.

Cramping

0



1



2



3



6.

Gnawing

0



1



2



3



7.

Hot-burning

0



1



2



3



8.

Aching

0



1



2



3



0



1



2



3



9.
Heavy (like a
weight)
10.

Tender

0



1



2



3



11.

Splitting

0



1



2



3



12.

Tiring-Exhausting

0



1



2



3



13.

Sickening

0



1



2



3



14.

Fear-causing

0



1



2



3



15.

Punishing-Cruel

0



1



2



3



II. B. PLEASE RATE YOUR PAIN DURING THE LAST WEEK.
The following line represents pain of increasing intensity from “no pain” to “worst possible
pain”. Place a vertical mark (|) across the line in the position that best describes your
pain during the last week.

No
Pain

Worst
Possible
Pain
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Score in mm

(Investigator’s use
only)

III. C. CURRENT PAIN INTENSITY
0  No pain
1  Mild
2  Discomforting
3  Distressing
4  Horrible
5  Excruciating

Questionnaire Developed by: Ronald Melzack

Copyright R. Melzack, 1970, 1987
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